AU2019343273A1 - Use of the fungicide Isoflucypram for controlling Claviceps purpurea and reducing sclerotia in cereals - Google Patents

Abstract

The invention relates to the use of the fungicide Isoflucypram, for controlling

Description

Use of the fungicide Isoflucypram for controlling Claviceps purpurea and reducing sclerotia in cereals

The invention relates to the use of the fungicide Isoflucypram for controlling Claviceps purpurea and reducing sclerotia in cereals, to a method for treating cereal plants, plant parts thereof, for controlling Claviceps purpurea and reducing sclerotia in cereal plants.

Claviceps purpurea is the fungus causing so called ergot in grasses like rye and ryegrass (principal economic hosts), barley, oats, triticale, wheat, and other cultivated and wild grass species in the subfamily Pooideae, including bentgrass, bluegrass and fescue. Claviceps purpurea is unique as the fungus only infects ovaries of the host plant. During the infection of the host plant the plant ovary is replaced by a blackish sclerotia often called an ergot or ergot body. The sclerotia are the overwintering spore form of the fungus which will partly be harvested with the crop and will partly fall to the ground. The sclerotia will need a vernalization period of about four to eight weeks with temperatures between 0 and 10 degree Celsius in order to break dormancy and germinate. The sclerotium consists of a whitish mycelial tissue containing storage cells and a dark pigmented outer cortex that protects the fungal mycelia from desiccation, UV light and other adverse environmental conditions. Due to its unique infection mode open pollinated cereal species are highly susceptible to infection, in particular rye and triticale.

The main problem of the disease is besides yield reduction the toxic alkaloids of the sclerotia causing significant health issues both in animals and plants. Poisoning outbreaks are called ergotism and have already described in the middle ages where consumption of flour ground from rye seed contaminated with ergot bodies led to gangrene, mental hallucinations and convulsions. Claviceps purpurea infection benefits from cooler and more humid weather conditions during the flowering period of the cereal plant. The disease is managed using different techniques like seed cleaning, planting of clean seed, sanitation of field borders and weed control, crop rotation or deep plowing. To determine the severeness of the disease, typically the amount of sclerotia/ergot bodies is assessed in the grain, as it is highly difficult to assess the disease in earlier stages of the infection. The assessment of the amount of honey dew produced by the fungus during infection is not predictive for the amount of sclerotia present in the grain. Consequently the presence of sclerotia also called ergot or ergot bodies in harvested grain of different types is a grading factor e.g. in the Official Grain Guiding Guide of Canada. Already low levels of ergot will lead to downgrading of grain, in particular in grain of higher quality like registered, certified or breeder grade. In grain which is meant for human and animal consumption like rye or wheat, tolerance levels are much lower than in grain not consumed by humans or animals like it is the case for forage grass. For forage grasses, a maximum of 3 % ergot bodies in the seed, ie up to 3 ergot bodies per 100 kernels of seed (Foundation/Registered/Certified/Common) is tolerated. For wheat grain meant for food and feed, the threshold is much lower with 0.04 % by weight. However fungicides capable of controlling Claviceps purpurea which would solve the underlying problem in a highly efficient manner are rare. So far azoxystrobin or propiconazole are labelled for the use against ergot in the Pacific Northwest. Recently a study described the use of eight different fungicidal products (azoxystrobin/propiconazole, boscalid, dicloran, fluazinam, fluopyram/ prothioconazole, pentachloronitrobenzene, picoxystrobin/cyproconazole, fluxapyroxad/pyraclostrobin as soil applied fungicides in perennial grasses (Dung et al, Crop Protection 106 (2018), pp 146-149) with the objective to find a more environmental sustainable solution in perennial grasses to eliminate ergot bodies of the soil instead of open field burning. Furthermore, in many areas of annual cereal production, perennial grasses are grown in ditches, roadsides and riparian areas to stabilize high slope soils and thereby prevent soil erosion. Since many species of forage grasses are susceptible to ergot, these areas act as a perennial reservoir of ergot inoculum which then infects cereal crops on an annual basis. In addition, control of ergot bodies in harvested grain of classical cereals like rye, barley, wheat meant for human or animal consumption, a significantly higher degree of control is needed. In particular in hybrid cereals like hybrid wheat there is a strong need to control Claviceps and prevent ergot body formation as the male sterile plants flower for a longer period of time and are thereby more susceptible.

There is therefore an urgent need for fungicides which enable sufficient control of Claviceps purpurea in cereal plants.

WO 2010/130767 and EP 3000809 A1 disclose fungicide pyrazole carboxamides derivatives, for example fsoflucypram, i.e. N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-l-methyl-lH- pyrazole-4-carboxamide (Example 29), which are utilized against different fungi. However, it is not apparent from the teaching of the publication which specific pyrazole carboxamides fungicides are suitable for treatment of Claviceps purpurea. More particularly, neither WO 2010/130767, EP 3000809 A1 nor any other document explicitly discloses the suitability of fsoflucypram for control of Claviceps purpurea and/or reduction of sclerotia. Even more particularly, neither WO 2010/130767 nor any other document explicitly discloses the suitability of fsoflucypram for the control of Claviceps purpurea in cereal plants and/or reduction of sclerotia using foliar application.

WO 2017/194363 discloses fungicidal ternary combinations comprising (A) fenpicoxamid, (B) isoflucypram and (C) one further compound selected from prothioconazole, fluopyram and tebuconazole. WO 2017/194363 discloses that said ternary combinations are particularly suitable for controlling specific cereals diseases, wherein said cereals diseases are caused by Mycosphaerella sp., Puccinia sp., Leptosphaeria sp., Pyrenophora sp., Ramularia sp., Gaeumannomyces sp., Fusarium sp., Giberella sp. Monographella sp., Septoria sp., Cochliobolus sp., and Rhynchosporium sp.. However, WO 2017/194363 does not explicitly disclose and does not show that said ternary combinations are effective against Claviceps purpurea in cereals. More particularly, WO 2017/194363 does not disclose the suitability of Isoflucypram for the control of Claviceps purpurea in cereal plants and/or reduction of sclerotia in cereal plants using foliar application.

WO 2016/096782 discloses fungicidal ternary combinations comprising (A) isoflucypram, (B) prothioconazole and (C) trifloxystrobin, tebuconazole, or fluopyram. Notably, the specific combination of isoflucypram, prothioconazole and tebuconazole is disclosed and shown to be effective against Septoria tritici in wheat, Puccinia triticina in wheat, Leptoshaeria nodorum in wheat and Pyrenophora teres in barley. However, WO 2016/096782 does not explicitly disclose and does not show that said ternary combinations are effective against Claviceps purpurea in cereals. More particularly, WO 2017/194363 does not disclose the suitability of Isoflucypram for control of Claviceps purpurea in cereal plants and/or reduction of sclerotinia in cereal plants using foliar application.

It has now been found that, surprisingly, the fungicide Isoflucypram is particularly suitable for control of Claviceps purpurea and/or for reduction of sclerotia of Claviceps purpurea in cereal plants, plant parts thereof, plant propagation material or the soil in which cereal plants are grown or intended to be grown. It has also been found that the use of Isoflucypram is particular suitable to control Claviceps purpurea and for reduction of sclerotia of Claviceps purpurea in hybrid cereals, in particular hybrid wheat and in hybrid wheat seed production. It has been found that Isoflucypram is able to control Claviceps purpurea and for reduction of sclerotia of Claviceps purpurea in cereals, in particular in hybrid cereals such as hybrid wheat and in hybrid wheat seed production, at a surprising low dose rate. It has been found that Isoflucypram is able to control Claviceps purpurea using foliar application.

The use of Isoflucypram for control of Claviceps purpurea and/or for reduction of sclerotia of Claviceps purpurea in hybrid wheat has been found to be particularly advantageous.

In an alternative embodiment of the invention, combinations comprising Isoflucypram and a further fungicide can be used for control of Claviceps purpurea in cereal plants.

The present invention accordingly provides for the use of the fungicide Isoflucypram for control of Claviceps purpurea and/or for reduction of sclerotia of Claviceps purpurea. In another embodiment the use of the fungicide Isoflucypram in hybrid wheat production methods for control of Claviceps purpurea and/or for reduction of sclerotia of Claviceps purpurea is described.

Isoflucypram has the chemical name N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5- fluoro-1 -methyl- lH-pyrazole-4-carboxamide and is a compound according to formula (I)

and suitable processes for preparation thereof, proceeding from commercially available starting materials, are described in WO 2010/130767, WO 2014/060518.

Isoflucypram, and/or the other compounds used in the present invention, may be present in the form of different stereoisomers. These stereoisomers are, for example, enantiomers, diastereomers, atropisomers or geometric isomers. Accordingly, the invention encompasses both pure stereoisomers and any mixture of these isomers. Where a compound can be present in two or more tautomer forms in equilibrium, reference to the compound by means of one tautomeric description is to be considered to include all tautomer forms. Isoflucypram, and/or the other compounds used in the present invention, may be present in the form of the free compound and/or an agrochemically active salt thereof.

Agrochemically active salts include acid addition salts of inorganic and organic acids well as salts of customary bases. Examples of inorganic acids are hydrohalic acids, such as hydrogen fluoride, hydrogen chloride, hydrogen bromide and hydrogen iodide, sulfuric acid, phosphoric acid and nitric acid, and acidic salts, such as sodium bisulfate and potassium bisulfate. Useful organic acids include, for example, formic acid, carbonic acid and alkanoic acids such as acetic acid, trifluoroacetic acid, trichloroacetic acid and propionic acid, and also glycolic acid, thiocyanic acid, lactic acid, succinic acid, citric acid, benzoic acid, cinnamic acid, oxalic acid, saturated or mono- or diunsaturated fatty acids having 6 to 20 carbon atoms, alkylsulphuric monoesters, alkylsulphonic acids (sulphonic acids having straight- chain or branched alkyl radicals having 1 to 20 carbon atoms), arylsulphonic acids or aryldisulphonic acids (aromatic radicals, such as phenyl and naphthyl, which bear one or two sulphonic acid groups), alkylphosphonic acids (phosphonic acids having straight- chain or branched alkyl radicals having 1 to 20 carbon atoms), arylphosphonic acids or aryldiphosphonic acids (aromatic radicals, such as phenyl and naphthyl, which bear one or two phosphonic acid radicals), where the alkyl and aryl radicals may bear further substituents, for example p-toluenesulphonic acid, salicylic acid, p- aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, etc.

Solvates of isoflucypram or its salts are stoichiometric compositions of the compounds with solvents.

Isoflucypram, and/or the other compounds used in the present invention, may exist in multiple crystalline and/or amorphous forms. Crystalline forms include unsolvated crystalline forms, solvates and hydrates.

In the context of the present invention, "control of Claviceps purpurea " means a significant reduction in infestation by Claviceps purpurea, compared with the untreated plant, preferably a significant reduction (by 40-79%), compared with the untreated plant (0% infection reduction); more preferably, the infection by Claviceps purpurea is entirely suppressed (by 70-100%). The control may be curative, i.e. for treatment of already infected plants, or protective, for protection of plants which have not yet been infected.

In the context of the present invention, "reduction of sclerotia of Claviceps purpurea " or "control of Claviceps purpurea "means a significant reduction in the number of sclerotia of Claviceps purpurea, compared with the untreated plant, preferably a significant reduction (by 40-79%), compared with the untreated plant (0% infection reduction); more preferably, the infection by Claviceps purpurea is entirely suppressed (by 70-100%). The amount of sclerotia can be measured either pre-harvest or post harvest in the grain. The control may be curative, i.e. for treatment of already infected plants, or protective, for protection of plants which have not yet been infected.

In the context of the present invention, a plant is preferably understood to mean a plant at or after the stage of leaf development (at or after BBCH stage 10 according to the BBCH monograph from the German Federal Biological Research Centre for Agriculture and Forestry, 2nd edition, 2001). In the context of the present invention, the term "plant" is also understood to mean seed or seedlings.

Cereals is defined to be cultivated crops of the Poaceae. In particular cereals are selected from the group of rye, oat, barley, triticale, wheat (spring wheat or winter wheat), durum. More preferred including barley, rye, triticale, spring wheat, hybrid spring wheat, durum, or hybrid winter wheat, hybrid winter wheat.

Preferably wheat is selected to be hybrid spring wheat, durum, or hybrid winter wheat, hybrid winter wheat.

The present invention also relates to the use of isoflucypram for the control of Gaeumannomyces diseases and/or take-all disease, particularly for the control of Gaeumannomyces graminis. Take-all is a plant disease caused by Gaeumannomyces graminis which infects the roots of the plants, particularly of grass and cereal plants (especially wheat, barley, rye, triticale, durum), and causes symptoms such as yellowing and stunting, reduced- tillering, blackened roots. Gaeumannomyces graminis also produces extensive damage on the sheath of rice, causing black spots, and/or discoloration in the foliage of the plant.

Uses

The treatment of the plants and plant parts with Isoflucypram or compositions comprising Isoflucypram is carried out directly or by acting on the environment, habitat or storage space using customary treatment methods, for example by dipping, spraying, atomizing, misting, evaporating, dusting, fogging, scattering, foaming, painting on, spreading, injecting, drenching, trickle irrigation and, in the case of propagation material, in particular in the case of seed, furthermore by the dry seed treatment method, the wet seed treatment method, the slurry treatment method, by encrusting, by coating with one or more coats and the like. It is furthermore possible to apply the active substances by the ultra-low volume method or to inject the active substance preparation or the active substance itself into the soil.

A preferred direct treatment of the plants is the leaf application treatment, i.e. Isoflucypram or compositions comprising Isoflucypram are applied to the foliage, it being possible for the treatment frequency and the application rate to be matched to the infection pressure of the Claviceps purpurea in question.

In the case of systemically active compounds, Isoflucypram or compositions comprising Isoflucypram reach the plants via the root system. In this case, the treatment of the plants is effected by allowing Isoflucypram or compositions comprising Isoflucypram to act on the environment of the plant. This can be done for example by drenching, incorporating in the soil or into the nutrient solution, i.e. the location of the plant (for example the soil or hydroponic systems) is impregnated with a liquid form of Isoflucypram or compositions comprising Isoflucypram, or by soil application, i.e. the Isoflucypram or compositions comprising Isoflucypram are incorporated into the location of the plants in solid form (for example in the form of granules). More particularly, the inventive use exhibits the advantages described on cereal plants, plant parts thereof, plant propagation material or the soil in which cereal plants are grown or intended to be grown in spray application using compositions comprising Isoflucypram.

Combinations of Isoflucypram, with substances including insecticides, fungicides and bactericides, fertilizers, growth regulators, can likewise find use in the control of plant diseases in the context of the present invention. The combined use of Isoflucypram, with hybrid crops, especially of hybrid wheat, is additionally likewise possible.

The use of Isoflucypram is effected preferably with a dosage between 0.001 and 1 kg of Isoflucypram /ha, more preferably between 0.002 and 0.5 kg of Isoflucypram /ha, more preferably between 0.005 and 0.4 kg of Isoflucypram /ha, even more preferably between 7 and 150 g of Isoflucypram /ha and most preferably between 10 and 120 g / of Isoflucypram/ha. A dosage of 15 to 100 g of Isoflucypram /ha, preferably from 20 to 70 g of Isoflucypram /ha is also disclosed.

In another embodiment the dosage is between 40 and 150 g/h, preferably between 30 and 120 g of Isoflucypram /ha, more preferably between 25 and 100 g of Isoflucypram /ha, mostly preferred between 20 and 90 g of Isoflucypram /ha.

Formulations

In one embodiment fungicidal compositions comprising Isoflucypram are described which further comprise agriculturally suitable auxiliaries, solvents, carriers, surfactants or extenders.

According to the invention, a carrier is a natural or synthetic, organic or inorganic substance with which the active ingredients are mixed or combined for better applicability, in particular for application to plants or plant parts or seed. The carrier, which may be solid or liquid, is generally inert and should be suitable for use in agriculture.

Useful solid carriers include: for example ammonium salts and natural rock flours, such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and synthetic rock flours, such as finely divided silica, alumina and silicates; useful solid carriers for granules include: for example, crushed and fractionated natural rocks such as calcite, marble, pumice, sepiolite and dolomite, and also synthetic granules of inorganic and organic flours, and granules of organic material such as paper, sawdust, coconut shells, maize cobs and tobacco stalks; useful emulsifiers and/or foam-formers include: for example non-ionic and anionic emulsifiers, such as polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, for example alkylaryl polyglycol ethers, alkylsulphonates, alkyl sulphates, arylsulphonates and also protein hydrolysates; suitable dispersants are nonionic and/or ionic substances, for example from the classes of the alcohol-POE and/or -POP ethers, acid and/or POP POE esters, alkylaryl and/or POP POE ethers, fat and/or POP POE adducts, POE- and/or POP-polyol derivatives, POE- and/or POP-sorbitan or -sugar adducts, alkyl or aryl sulphates, alkyl- or arylsulphonates and alkyl or aryl phosphates or the corresponding PO-ether adducts. Additionally suitable are oligo- or polymers, for example those derived from vinylic monomers, from acrylic acid, from EO and/or PO alone or in combination with, for example, (poly)alcohols or (poly)amines. It is also possible to use lignin and its sulphonic acid derivatives, unmodified and modified celluloses, aromatic and/or aliphatic sulphonic acids and also their adducts with formaldehyde.

Isoflucypram can be converted to the customary formulations, such as solutions, emulsions, emulsifiable concentrates, wettable powders, water- and oil-based suspensions, powders, dusts, pastes, soluble powders, soluble granules, granules for broadcasting, suspoemulsion concentrates, natural products impregnated with active ingredient, synthetic substances impregnated with active ingredient, fertilizers and also microencapsulations in polymeric substances.

Isoflucypram can be applied as such, in the form of its formulations or the use forms prepared therefrom, such as ready-to-use solutions, emulsions, water- or oil-based suspensions, powders, wettable powders, pastes, soluble powders, dusts, soluble granules, granules for broadcasting, suspoemulsion concentrates, natural products impregnated with active ingredient, synthetic substances impregnated with active ingredient, fertilizers and also microencapsulations in polymeric substances. Application is accomplished in a customary manner, for example by watering, spraying, atomizing, broadcasting, dusting, foaming, spreading-on and the like. It is also possible to deploy the active ingredients by the ultra-low volume method or to inject the active ingredient preparation/the active ingredient itself into the soil. It is also possible to treat the seed of the plants.

The formulations mentioned can be prepared in a manner known per se, for example by mixing the active ingredients with at least one customary extender, solvent or diluent, emulsifier, dispersant and/or binder or fixing agent, wetting agent, a water repellent, if appropriate siccatives and UV stabilizers and if appropriate dyes and pigments, antifoams, preservatives, secondary thickeners, stickers, gibberellins and also other processing auxiliaries.

The present invention includes not only formulations which are already ready for use and can be deployed with a suitable apparatus to the plant or the seed, but also commercial concentrates which have to be diluted with water prior to use.

Isoflucypram may be present as such or in its (commercial) formulations and in the use forms prepared from these formulations as a mixture with other (known) active ingredients, such as insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth regulators, herbicides, fertilizers, safeners and/or semiochemicals.

The auxiliaries used may be those substances which are suitable for imparting particular properties to the composition itself or and/or to preparations derived therefrom (for example spray liquors, seed dressings), such as certain technical properties and/or also particular biological properties. Typical auxiliaries include: extenders, solvents and carriers. Suitable extenders are, for example, water, polar and nonpolar organic chemical liquids, for example from the classes of the aromatic and nonaromatic hydrocarbons (such as paraffins, alkylbenzenes, alkylnaphthalenes, chlorobenzenes), the alcohols and polyols (which may optionally also be substituted, etherified and/or esterified), the ketones (such as acetone, cyclohexanone), esters (including fats and oils) and (poly)ethers, the unsubstituted and substituted amines, amides, lactams (such as N-alkylpyrrolidones) and lactones, the sulphones and sulphoxides (such as dimethyl sulphoxide).

Liquefied gaseous extenders or carriers are understood to mean liquids which are gaseous at standard temperature and under standard pressure, for example aerosol propellants such as halohydro carbons, or else butane, propane, nitrogen and carbon dioxide.

In the formulations it is possible to use tackifiers such as carboxymethylcellulose, natural and synthetic polymers in the form of powders, granules or latices, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, or else natural phospholipids such as cephalins and lecithins and synthetic phospholipids. Further additives may be mineral and vegetable oils.

If the extender used is water, it is also possible to use, for example, organic solvents as auxiliary solvents. Useful liquid solvents are essentially: aromatics such as xylene, toluene or alkylnaphthalenes, chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons such as cyclohexane or paraffins, for example petroleum fractions, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents such as dimethylformamide and dimethyl sulphoxide, or else water.

Compositions comprising Isoflucypram may additionally comprise further components, for example surfactants. Suitable surfactants are emulsifiers and/or foam formers, dispersants or wetting agents having ionic or nonionic properties, or mixtures of these surfactants. Examples thereof are salts of polyacrylic acid, salts of lignosulphonic acid, salts of phenolsulphonic acid or naphthalenesulphonic acid, polycondensates of ethylene oxide with fatty alcohols or with fatty acids or with fatty amines, substituted phenols (preferably alkylphenols or arylphenols), salts of sulphosuccinic esters, taurine derivatives (preferably alkyl taurates), phosphoric esters of polyethoxylated alcohols or phenols, fatty esters of polyols, and derivatives of the compounds containing sulphates, sulphonates and phosphates, for example alkylaryl polyglycol ethers, alkylsulphonates, alkyl sulphates, arylsulphonates, protein hydrolysates, lignosulphite waste liquors and methylcellulose. The presence of a surfactant is necessary if one of the active ingredients and/or one of the inert carriers is insoluble in water and when application is effected in water. The proportion of surfactants is between 5 and 40 per cent by weight of the inventive composition.

Further additives may be perfumes, mineral or vegetable, optionally modified oils, waxes and nutrients (including trace nutrients), such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc. Additional components may be stabilizers, such as cold stabilizers, preservatives, antioxidants, light stabilizers, or other agents which improve chemical and/or physical stability.

If appropriate, other additional components may also be present, for example protective colloids, binders, adhesives, thickeners, thixotropic substances, penetrants, stabilizers, sequestering agents, complex formers. In general, the active ingredients can be combined with any solid or liquid additive commonly used for formulation purposes.

The formulations contain generally between 0.05 and 99% by weight, 0.01 and 98% by weight, preferably between 0.1 and 95% by weight, more preferably between 0.5 and 90% of active ingredient, most preferably between 10 and 70 per cent by weight.

In one embodiment formulations of Isoflucypram comprise 1 to 300 g/L Isoflucypram as an EC, SC, SE or SL formulation, preferably 10 to 250 g/L Isoflucypram, as an EC or SC formulation.

The formulations described above may be used for control of Claviceps purpurea, in which the compositions comprising Isoflucypram are applied to cereal plants.

Plants

According to the invention all plants and plant parts can be treated. By plants is meant all plants and plant populations such as desirable and undesirable wild plants, cultivars and plant varieties (whether or not protectable by plant variety or plant breeder’s rights). Cultivars and plant varieties can be plants obtained by conventional propagation and breeding methods which can be assisted or supplemented by one or more biotechnological methods such as by use of double haploids, protoplast fusion, random and directed mutagenesis, molecular or genetic markers or by bioengineering and genetic engineering methods. By plant parts is meant all above ground and below ground parts and organs of plants such as shoot, leaf, blossom and root, whereby for example leaves, needles, stems, branches, blossoms, fruiting bodies, fruits and seed as well as roots, corms and rhizomes are listed. Crops and vegetative and generative propagating material, for example cuttings, corms, rhizomes, runners, slips and seeds also belong to plant parts.

In one embodiment crop plants belonging to the plant family cereals are cereal plants.

In a preferred embodiment crop species, cultivars and varieties belonging to the cereal plants are rye, oats, barley triticale, wheat (spring wheat or winter wheat), hybrid wheat (spring wheat or winter wheat), and durum.

More preferred plants, plant parts or seeds according to the present invention are wheat plants, plant parts or seeds, hybrid wheat plants, plant parts or seeds; more preferred hybrid winter wheat plants, plant parts or seeds, hybrid spring wheat plants, plant parts or seeds. In one aspect wheat plants or plant parts are hybrid plants or plant parts. In another aspect spring wheat plants or plant parts are spring hybrid plants or plant parts. . In another aspect winter wheat plants or plant parts are winter hybrid plants or plant parts.

The term "growth stage" refers to the growth stages as defined by the BBCH Codes in "Growth stages of mono- and dicotyledonous plants", 2nd edition 2001, edited by Uwe Meier from the Federal Biological Research Centre for Agriculture and Forestry. The BBCH codes are a well-established system for a uniform coding of phonologically similar growth stages of all mono- and dicotyledonous plant species. The abbreviation BBCH derives from "Biologische Bundesanstalt, Bundessortenamt und Chemische Industrie".

Some of these BBCH growth stages and BBCH codes for cereal plants are indicated in the following.

Growth stage 0: Germination

00 Dry seed (caryopsis)

01 Beginning of seed imbibition

03 Seed imbibition complete

05 Radicle emerged from caryopsis

06 Radicle elongated, root hairs and/or side roots visible

07 Coleoptile emerged from caryopsis

09 Emergence: coleoptile penetrates soil surface (cracking stage)

Growth stage 1 : Leaf development 1

10 First leaf through coleoptile

11 First leaf unfolded

12 2 leaves unfolded

13 3 leaves unfolded

1 . Stages continuous till . . .19 9 or more leaves unfolded

Growth stage 2: Tillering

20 No tillers

21 Beginning of tillering: first tiller detectable

22 2 tillers detectable

23 3 tillers detectable

2 . Stages continuous till . . .29 End of tillering. Maximum no. of tillers detectable Growth stage 3 : Stem elongation

30 Beginning of stem elongation: pseudostem and tillers erect, first intemode begins to elongate, top of inflorescence at least 1 cm above tillering node

31 First node at least 1 cm above tillering node

32 Node 2 at least 2 cm above node 1

33 Node 3 at least 2 cm above node 2 3 . Stages continuous till . . .37 Flag leaf just visible, still rolled

39 Flag leaf stage: flag leaf fully unrolled, ligule just visible

Principal growth stage 4: Booting

41 Early boot stage: flag leaf sheath extending

43 Mid boot stage: flag leaf sheath just visibly swollen

45 Late boot stage: flag leaf sheath swollen

47 Flag leaf sheath opening

49 First awns visible (in awned forms only)

Principal growth stage 5: Inflorescence emergence, heading

51 Beginning of heading: tip of inflorescence emerged from sheath, first spikelet just visible

52 20% of inflorescence emerged

53 30% of inflorescence emerged

54 40% of inflorescence emerged

55 Middle of heading: half of inflorescence emerged

56 60% of inflorescence emerged

57 70% of inflorescence emerged

58 80% of inflorescence emerged

59 End of heading: inflorescence fully emerged...

Principal growth stage 6: Flowering, anthesis

61 Beginning of flowering: first anthers visible

65 Full flowering: 50% of anthers mature

69 End of flowering: all spikelets have completed flowering but some dehydrated anthers may remain

Principal growth stage 7 : Development of fruit

71 Watery ripe: first grains have reached half their final size

73 Early milk

75 Medium milk: grain content milky, grains reached final size, still green

77 Late milk

Principal growth stage 8: Ripening

83 Early dough

85 Soft dough: grain content soft but dry. Fingernail impression not held

87 Hard dough: grain content solid. Fingernail impression held

89 Fully ripe: grain hard, difficult to divide with thumbnail

Principal growth stage 9: Senescence

92 Over-ripe: grain very hard, cannot be dented by thumbnail

93 Grains loosening in day-time 97 Plant dead and collapsing

99 Harvested product

Particular preference is given in accordance with the invention to treating plants of the plant cultivars which are each commercially available or in use. Plant cultivars are understood to mean plants which have new properties ("traits") and which have been obtained by conventional breeding, by mutagenesis or with the aid of recombinant DNA techniques. Crop plants may accordingly be plants which can be obtained by conventional breeding and optimization methods or by biotechnology and genetic engineering methods or combinations of these methods, including the transgenic plants and including the plant varieties which can and cannot be protected by plant variety rights.

The method according to the invention can thus also be used for the treatment of genetically modified organisms (GMOs), for example plants or seeds. Genetically modified plants (or transgenic plants) are plants in which a heterologous gene has been integrated stably into the genome. The term "heterologous gene" means essentially a gene which is provided or assembled outside the plant and which, on introduction into the cell nucleus genome, imparts new or improved agronomic or other properties to the chloroplast genome or the mitochondrial genome of the transformed plant by virtue of it expressing a protein or polypeptide of interest or by virtue of another gene which is present in the plant, or other genes which are present in the plant, being downregulated or silenced (for example by means of antisense technology, co-suppression technology or RNAi technology [RNA interference]). A heterologous gene present in the genome is likewise referred to as a transgene. A transgene which is defined by its specific presence in the plant genome is referred to as a transformation or transgenic event.

Plants and plant cultivars which are preferably treated according to the invention include all plants which have genetic material which imparts particularly advantageous, useful traits to these plants (whether obtained by breeding and/or biotechnological means). These plants may have been modified by mutagenesis or genetic engineering to provide a new trait to a plant or to modify an already present trait. Mutagenesis includes techniques of random mutagenesis using X-rays or mutagenic chemicals, but also techniques of targeted mutagenesis, to create mutations at a specific locus of a plant genome. Targeted mutagenesis techniques frequently use oligonucleotides or proteins like CRISPR/Cas, zinc-finger nucleases, TALENs or mega nucleases to achieve the targeting effect. Genetic engineering usually uses recombinant DNA techniques to create modifications in a plant genome which under natural circumstances cannot readily be obtained by cross breeding, mutagenesis or natural recombination. Typically, one or more genes are integrated into the genome of a plant to add a trait or improve a trait. These integrated genes are also referred to as transgenes in the art, while plant comprising such transgenes are referred to as transgenic plants. The process of plant transformation usually produces several transformation events, wich differ in the genomic locus in which a transgene has been integrated. Plants comprising a specific transgene on a specific genomic locus are usually described as comprising a specific "event", which is referred to by a specific event name. Traits which have been introduced in plants or have been modified include herbicide tolerance, insect resistance, increased yield and tolerance to abiotic conditions, like drought. Herbicide tolerance has been created by using mutagenesis as well as using genetic engineering.

Plants and plant cultivars which may also be treated in according to invention are those plants which are resistant to one or more abiotic stresses. Abiotic stress conditions may include, for example, drought, cold temperature exposure, heat exposure, osmotic stress, flooding, increased soil salinity, increased mineral exposure, ozone exposure, high light exposure, limited availability of nitrogen nutrients, limited availability of phosphorus nutrients or shade avoidance.

Plants and plant cultivars which may also be treated according to the invention are those plants characterized by enhanced yield characteristics. Increased yield in said plants can be the result of, for example, improved plant physiology, growth and development, such as water use efficiency, water retention efficiency, improved nitrogen use, enhanced carbon assimilation, improved photosynthesis, increased germination efficiency and accelerated maturation. Yield can furthermore be affected by improved plant architecture (under stress and non-stress conditions), including but not limited to early flowering, flowering control for hybrid seed production, seedling vigour, plant size, intemode number and distance, root growth, seed size, fruit size, pod size, pod or ear number, seed number per pod or ear, seed mass, enhanced seed filling, reduced seed dispersal, reduced pod dehiscence and lodging resistance. Further yield traits include seed composition, such as carbohydrate content, protein content, oil content and composition, nutritional value, reduction in anti- nutritional compounds, improved processability and better storage stability.

Plants that may also be treated according to the invention are hybrid plants that already express the characteristic of heterosis or hybrid vigour which generally results in higher yield, vigour, health and resistance towards biotic and abiotic stress factors. Such plants are typically made by crossing an inbred male-sterile parent line (the female parent) with another inbred male-fertile parent line (the male parent). Hybrid seed is typically harvested from the male sterile plants and sold to growers. Male sterile plants can sometimes (e.g. in maize) be produced by detasseling, i.e. the mechanical removal of the male reproductive organs (or male flowers), but, more typically, male sterility is the result of genetic determinants in the plant genome. In that case, and especially when seed is the desired product to be harvested from the hybrid plants, it is typically useful to ensure that male fertility in hybrid plants that contain the genetic determinants responsible for the male sterility is fully restored. This can be accomplished by ensuring that the male parents have appropriate fertility restorer genes which are capable of restoring the male fertility in hybrid plants that contain the genetic determinants responsible for male sterility. Genetic determinants for male sterility may be located in the cytoplasm. Examples of cytoplasmatic male sterility (CMS) were for instance described in Brassica species (WO 1992/005251, WO 1995/009910, WO 1998/27806, WO 2005/002324, WO 2006/021972 and US 6,229,072). However, genetic determinants for male sterility can also be located in the nuclear genome. Male- sterile plants can also be obtained by plant biotechnology methods such as genetic engineering. A particularly useful means of obtaining male-sterile plants is described in WO 89/10396, in which, for example, a ribonuclease such as bamase is selectively expressed in the tapetum cells in the stamens. Fertility can then be restored by expression in the tapetum cells of a ribonuclease inhibitor such as barstar (e.g. WO 1991/002069). Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may likewise be treated according to the invention are herbicide-tolerant plants, i.e. plants made tolerant to one or more given herbicides. Such plants can be obtained either by genetic transformation, or by selection of plants containing a mutation imparting such herbicide tolerance. Herbicide tolerance has been created via the use of transgenes to glyphosate, glufosinate, 2,4- D, dicamba, oxynil herbicides, like bromoxynil and ioxynil, sulfonylurea herbicides, ALS inhibitors and 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors, like isoxaflutole and mesotrione. Transgenes wich have been used to provide herbicide tolerance traits comprise: for tolerance to glyphosate: cp4 epsps, epsps grg23ace5, mepsps, 2mepsps, gat4601 , gat4621 , goxv247; for tolerance to glufosinate: pat and bar, for tolerance to 2,4-D: aad-1 , aad-12; for tolerance to dicamba: dmo; for tolerance to oxynil herbicies: bxn; for tolerance to sulfonylurea herbicides: zm-hra, csrl -2, gm-hra, S4-HrA; for tolerance to ALS inhibitors: csrl -2; and for tolerance to HPPD inhibitors: hppdPF, W336, avhppd-03.

Herbicide-tolerant plants are for example glyphosate-tolerant plants, i.e. plants made tolerant to the herbicide glyphosate or salts thereof. For example, glyphosate-tolerant plants can be obtained by transforming the plant with a gene encoding the enzyme 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS). Examples of such EPSPS genes are the AroA gene (mutant CT7) of the bacterium Salmonella typhimurium (Comai et ak, Science (1983), 221, 370-371), the CP4 gene of the bacterium Agrobacterium sp. (Barry et ah, Curr. Topics Plant Physiol. (1992), 7, 139-145), the genes encoding a petunia EPSPS (Shah et ah, Science (1986), 233, 478-481), a tomato EPSPS (Gasser et ah, J. Biol. Chem. (1988), 263, 4280-4289) or an Eleusine EPSPS (WO 2001/66704). It can also be a mutated EPSPS, as described, for example, in EP-A 0837944, WO 2000/066746, WO 2000/066747 or WO 2002/026995. Glyphosate-tolerant plants can also be obtained by expressing a gene that encodes a glyphosate oxidoreductase enzyme as described in US 5,776,760 and US 5,463,175. Glyphosate- tolerant plants can also be obtained by expressing a gene that encodes a glyphosate acetyl transferase enzyme as described, for example, in WO 2002/036782, WO 2003/092360, WO 2005/012515 and WO 2007/024782. Glyphosate-tolerant plants can also be obtained by selecting plants containing naturally occurring mutations of the above-mentioned genes as described, for example, in WO 2001/024615 or WO 2003/013226.

Other herbicide-resistant plants are for example plants that have been made tolerant to herbicides inhibiting the enzyme glutamine synthase, such as bialaphos, phosphinothricin or glufosinate. Such plants can be obtained by expressing an enzyme detoxifying the herbicide or a mutant glutamine synthase enzyme that is resistant to inhibition. One such efficient detoxifying enzyme is, for example, an enzyme encoding a phosphinothricin acetyltransferase (such as the bar or pat protein from Streptomyces species). Plants expressing an exogenous phosphinothricin acetyltransferase are for example described in US 5,561,236; US 5,648,477; US 5,646,024; US 5,273,894; US 5,637,489; US 5,276,268; US 5,739,082; US 5,908,810 and US 7,112,665.

Further herbicide-tolerant plants are also plants that have been made tolerant to the herbicides inhibiting the enzyme hydroxyphenylpyruvatedioxygenase (HPPD). Hydroxyphenylpyruvatedioxygenases are enzymes that catalyse the reaction in which para-hydroxyphenylpyruvate (HPP) is transformed into homogentisate. Plants tolerant to HPPD-inhibitors can be transformed with a gene encoding a naturally occurring resistant HPPD enzyme, or a gene encoding a mutated HPPD enzyme according to WO 1996/038567, WO 1999/024585 and WO 1999/024586. Tolerance to HPPD inhibitors can also be obtained by transforming plants with genes encoding certain enzymes enabling the formation of homogentisate despite the inhibition of the native HPPD enzyme by the HPPD inhibitor. Such plants and genes are described in WO 1999/034008 and WO 2002/36787. Tolerance of plants to HPPD inhibitors can also be improved by transforming plants with a gene encoding an enzyme prephenate dehydrogenase in addition to a gene encoding an HPPD-tolerant enzyme, as described in WO 2004/024928.

Further herbicide-resistant plants are plants that have been made tolerant to acetolactate synthase (ALS) inhibitors. Known ALS-inhibitors include, for example, sulphonylurea, imidazolinone, triazolopyrimidines, pyrimidinyloxy(thio)benzoates, and/or sulphonylaminocarbonyltriazolinone herbicides. Different mutations in the ALS enzyme (also known as acetohydroxyacid synthase, AHAS) are known to confer tolerance to different herbicides and groups of herbicides, as described for example in Tranel and Wright, Weed Science (2002), 50, 700-712, but also in US 5,605,011, US 5,378,824, US 5,141,870 and US 5,013,659. The production of sulphonylurea-tolerant plants and imidazolinone-tolerant plants is described in US 5,605,011; US 5,013,659; US 5,141,870; US 5,767,361; US 5,731,180; US 5,304,732; US 4,761,373; US 5,331,107; US 5,928,937; and US 5,378,824; and international publication WO 1996/033270. Other imidazolinone-tolerant plants are also described in for example WO 2004/040012, WO 2004/106529, WO 2005/020673, WO 2005/093093, WO 2006/007373, WO 2006/015376, WO 2006/024351 and WO 2006/060634. Further sulphonylurea- and imidazolinone-tolerant plants are also described in for example WO 2007/024782.

Other plants tolerant to imidazolinone and/or sulphonylurea can be obtained by induced mutagenesis, selection in cell cultures in the presence of the herbicide or by mutation breeding as described for example for soya beans in US 5,084,082, for rice in WO 1997/41218, for sugar beet in US 5,773,702 and WO 1999/057965, for letuce in US 5,198,599 or for sunflower in WO 2001/065922.

Transgenic com events comprising herbicide tolerance genes include, but are not limited to, DAS40278, MON801 , MON802, MON809, MON810, MON832, MON8741 1 , MON87419, MON87427, MON88017, MON89034, NK603, GA21 , MZHG0JG, HCEM485, VCO-01981 -5, 676, 678, 680, 33121 , 41 14, 59122, 98140, BtlO, Btl76, CBH-351 , DBT418, DLL25, MS3, MS6, MZIR098, T25, TC1507 and TC6275. Transgenic soybean events comprising herbicide tolerance genes include, but are not limited to, GTS 40-3-2, MON87705, MON87708,MON87712, MON87769, MON89788, A2704-12, A2704-21 , A5547-127, A5547- 35, DP356043, DAS44406-6, DAS68416-4, DAS-81419-2, GU262, SYHT0H2, W62, W98, FG72 and CV127. Transgenic coton events comprising herbicide tolerance genes include, but are not limited to, 19-51 a, 31707, 42317, 81910, 281 -24-236, 3006-210-23, BXN1021 1 , BXN10215, BXN10222, BXN10224, MON1445, MON 1698, MON88701 , MON88913, GHB 1 19, GHB614, LLCoton25, T303-3 and T304-40. Transgenic canola events comprising herbicide tolerance genes are for example, but not excluding others, MON88302, HCR-1 , HCN10, HCN28, HCN92, MSI , MS8, PHY 14, PHY23, PHY35, PHY36, RF1 , RF2 and RF3.

Insect resistance has mainly been created by transferring bacterial genes for insecticidal proteins to plants: Transgenes which have most frequently been used are toxin genes of Bacillus spp. and synthetic variants thereof, like crylA, crylAb, crylAb-Ac, crylAc, crylA.105, cryl F, cryl Fa2, cry2Ab2, cry2Ae, mcry3A, ecry3.1Ab, cry3Bbl , cry34Abl , cry35Abl , cry9C, vip3A(a), vip3Aa20. However, also genes of plant origin, such as genes coding for protease inhibitors, like CpTI and pin 11 , have been transferred to other plants. A further approach uses transgenes such as dvsnf7 to produce double-stranded RNA in plants.

Transgenic com events comprising genes for insecticidal proteins or double stranded RNA include, but are not limited to, BtlO, Btl 1 , Btl76, MON801 , MON802, MON809, MON810, MON863, MON8741 1 , MON88017, MON89034, 33121 , 41 14, 5307, 59122, TC1507, TC6275, CBH-351 , MIR162, DBT418 and MZIR098. Transgenic soybean events comprising genes for insecticidal proteins include, but are not limited to, MON87701 , MON87751 and DAS-81419. Transgenic cotton events comprising genes for insecticidal proteins include, but are not limited to, SGK321 , MON531 , MON757, MON1076, MON15985, 31707, 31803, 31807, 31808, 42317, BNLA-601 , Eventl , COT67B, COT102, T303-3, T304-40, GFM CrylA, GK12, MLS 9124, 281 - 24-236, 3006-210-23, GHB1 19 and SGK321.

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are tolerant to abiotic stress factors. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such stress resistance. Particularly useful stress-tolerant plants include: a. plants which contain a transgene capable of reducing the expression and/or the activity of the poly(ADP- ribose)polymerase (PARP) gene in the plant cells or plants as described in WO 2000/004173 or EP 04077984.5 or EP 06009836.5; b. plants which contain a stress tolerance-enhancing transgene capable of reducing the expression and/or the activity of the PARG encoding genes of the plants or plant cells as described, for example, in WO 2004/090140; c. plants which contain a stress tolerance-enhancing transgene coding for a plant- functional enzyme of the nicotinamide adenine dinucleotide salvage biosynthesis pathway, including nicotinamidase, nicotinate phosphoribosyltransferase, nicotinic acid mononucleotide adenyltransferase, nicotinamide adenine dinucleotide synthetase or nicotinamide phosphoribosyltransferase as described, for example, in EP 04077624.7 or WO 2006/133827 or PCT/EP07/002433.

Plants comprising singular or stacked traits as well as the genes and events providing these traits are well known in the art. For example, detailed information as to the mutagenized or integrated genes and the respective events are available from websites of the organizations "International Service for the Acquisition of Agri-biotech Applications (ISAAA)" and the "Center for Environmental Risk Assessment (CERA)". Foliar Application

The foliar treatment of plants has been known for a long time and is the subject of constant improvements. Nevertheless, the treatment of plants gives rise to a series of problems which cannot always be solved in a satisfactory manner. For instance, it is desirable to develop methods for protecting the plant, the developing inflorescence and seed. It is additionally desirable to optimize the amount of Isoflucypram used in such a way as to provide the best possible protection for the plant, in particular the developing inflorescence from attack by Claviceps purpurea, but without damaging the cereals plant itself by the active ingredient used.

In another embodiment a method for treating plants to control Claviceps purpurea in cereal plants at BBCH stage 50 or later by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to control Claviceps purpurea in cereal plants between BBCH stage 50 and 80 by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to reduce sclerotia of Claviceps purpurea in cereal plants at BBCH stage 90 or later by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to reduce sclerotia of Claviceps purpurea in cereal plants at BBCH stage 90 or later by treating the cereal plant between BBCH stage 50 and 80 with Isoflucypram.

In another embodiment a method for treating plants to control Claviceps purpurea in spring wheat, winter wheat, barley, rye, triticale, durum, hybrid spring wheat, hybrid winter wheat plants at BBCH stage 50 or later by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to control Claviceps purpurea in spring wheat, winter wheat, barley, rye, triticale, durum, hybrid spring wheat, hybrid winter wheat plants between BBCH stage 50 and 80 by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to reduce sclerotia of Claviceps purpurea in spring wheat, winter wheat, barley, rye, triticale, durum, hybrid spring wheat, hybrid winter wheat plants at BBCH stage 90 or later by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to reduce sclerotia of Claviceps purpurea in spring wheat, winter wheat, barley, rye, triticale, durum, hybrid spring wheat, hybrid winter wheat plants at BBCH stage 90 or later by treating the cereal plant between BBCH stage 50 and 80 with Isoflucypram.

In another embodiment a method for treating plants to control Claviceps purpurea in spring wheat plants at BBCH stage 50 or later by treating the cereal plant at BBCH stage 50 with Isoflucypram. In another embodiment a method for treating plants to control Claviceps purpurea in spring wheat plants between BBCH stage 50 and 80 by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to reduce sclerotia of Claviceps purpurea in spring wheat plants at BBCH stage 90 or later by treating the cereal plant at BBCH stage 50 with Isoflucypram. In another embodiment a method for treating plants to reduce sclerotia of Claviceps purpurea in spring wheat plants at BBCH stage 90 or later by treating the cereal plant between BBCH stage 50 and 80 with Isoflucypram.

In another embodiment a method for treating plants to control Claviceps purpurea in hybrid spring wheat plants at BBCH stage 50 or later by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to control Claviceps purpurea in hybrid spring wheat plants between BBCH stage 50 and 80 by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to reduce sclerotia of Claviceps purpurea in hybrid spring wheat plants at BBCH stage 90 or later by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to reduce sclerotia of Claviceps purpurea in hybrid spring wheat plants at BBCH stage 90 or later by treating the cereal plant between BBCH stage 50 and 80 with Isoflucypram.

In another embodiment a method for treating plants to control Claviceps purpurea in winter wheat plants at BBCH stage 50 or later by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to control Claviceps purpurea in winter wheat plants between BBCH stage 50 and 80 by treating the cereal plant at BBCH stage 50 with Isoflucypram. In another embodiment a method for treating plants to reduce sclerotia of Claviceps purpurea in winter wheat plants at BBCH stage 90 or later by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to reduce sclerotia of Claviceps purpurea in winter wheat plants at BBCH stage 90 or later by treating the cereal plant between BBCH stage 50 and 80 with Isoflucypram.

In another embodiment a method for treating plants to control Claviceps purpurea in hybrid winter wheat plants at BBCH stage 50 or later by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to control Claviceps purpurea in hybrid winter wheat plants between BBCH stage 50 and 80 by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to reduce sclerotia of Claviceps purpurea in hybrid winter wheat plants at BBCH stage 90 or later by treating the cereal plant at BBCH stage 50 with Isoflucypram. In another embodiment a method for treating plants to reduce sclerotia of Claviceps purpurea in hybrid winter wheat plants at BBCH stage 90 or later by treating the cereal plant between BBCH stage 50 and 80 with Isoflucypram.

In another embodiment a method for treating plants to control Claviceps purpurea in barley, rye, triticale or durum plants at BBCH stage 50 or later by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to control Claviceps purpurea in barley, rye, triticale or durum plants between BBCH stage 50 and 80 by treating the cereal plant at BBCH stage 50 with Isoflucypram.

In another embodiment a method for treating plants to reduce sclerotia of Claviceps purpurea in barley, rye, triticale or durum plants at BBCH stage 90 or later by treating the cereal plant at BBCH stage 50 with

Isoflucypram.

In another embodiment a method for treating plants to reduce sclerotia of Claviceps purpurea in barley, rye, triticale or durum plants at BBCH stage 90 or later by treating the cereal plant between BBCH stage 50 and 80 with Isoflucypram.

One of the advantages of the present invention is that, owing to the particular systemic properties of Isoflucypram, the treatment of the cereal plant during flowering with Isoflucypram, enables not only the control of Claviceps purpurea on the plant itself, but also on the developing seeds resulting in a reduction of sclerotia in the harvested grain.

Mixtures

Isoflucypram can be mixed with other active ingredients like fungicides, bactericides, acaricides, nematicides, insecticides, herbicides, fertilizers, growth regulators, safeners or semiochemicals. This may allow to broaden the activity spectrum or to prevent development of resistance. Examples of known fungicides, insecticides, acaricides, nematicides and bactericides are disclosed in the Pesticide Manual, 17th Edition.

Where a compound (A) or a compound (B) can be present in tautomeric form, such a compound is understood herein above and herein below also to include, where applicable, corresponding tautomeric forms, even when these are not specifically mentioned in each case.

All named mixing partners can, if their functional groups enable this, optionally form salts with suitable bases or acids.

Examples of especially preferred fungicides which could be mixed with Isoflucypram are:

1) Inhibitors of the ergosterol biosynthesis, for example (1.001) cyproconazole, (1.002) difenoconazole, (1.003) epoxiconazole, (1.004) fenhexamid, (1.005) fenpropidin, (1.006) fenpropimorph, (1.007) fenpyrazamine, (1.008) fluquinconazole, (1.009) flutriafol, (1.010) imazalil, (1.011) imazalil sulfate, (1.012) ipconazole, (1.013) metconazole, (1.014) myclobutanil, (1.015) paclobutrazol, (1.016) prochloraz, (1.017) propiconazole, (1.018) prothioconazole, (1.019) Pyrisoxazole, (1.020) spiroxamine, (1.021) tebuconazole, (1.022) tetraconazole, (1.023) triadimenol, (1.024) tridemorph, (1.025) triticonazole, (1.026) (lR,2S,5S)-5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-l-(lH-l,2,4-triazol-l- ylmethyl)cyclopentanol, (1.027) (l S,2R,5R)-5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-l-(lH-l,2,4- triazol-l-ylmethyl)cyclopentanol, (1.028) (2R)-2-(l-chlorocyclopropyl)-4-[(lR)-2,2- dichlorocyclopropyl] - 1 -( 1 H- 1 ,2,4-triazol- 1 -yl)butan-2-ol, ( 1.029) (2R)-2-( 1 -chlorocyclopropyl)-4- [( 1 S)- 2,2-dichlorocyclopropyl]-l-(lH-l,2,4-triazol-l-yl)butan-2-ol, (1.030) (2R)-2-[4-(4-chlorophenoxy)-2- (trifluoromethyl)phenyl] - 1 -( 1 H- 1 ,2,4-triazol- 1 -yl)propan-2-ol, (1.031) (2S)-2-( 1 -chlorocyclopropyl)-4- [( 1 R)-2,2-dichlorocyclopropyl] - 1 -( 1 H- 1 ,2,4-triazol- 1 -yl)butan-2-ol, (1.032) (2S)-2-( 1 - chlorocyclopropyl)-4-[(lS)-2,2-dichlorocyclopropyl]-l -(lH-l,2,4-triazol-l-yl)butan-2-ol, (1.033) (2S)- 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-l -(lH-l,2,4-triazol-l -yl)propan-2-ol, (1.034) (R)-[3- (4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-l,2-oxazol-4-yl](pyridin-3-yl)methanol, (1.035) (S)- [3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-l ,2-oxazol-4-yl](pyridin-3-yl)methanol, (1.036) [3- (4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-l,2-oxazol-4-yl](pyridin-3-yl)methanol, (1.037) 1-

({(2R,4S)-2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-l,3-dioxolan-2-yl}methyl)-lH-l, 2,4- triazole, (1.038) l-({(2S,4S)-2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-l,3-dioxolan-2- yl} methyl)- 1H- 1,2, 4-triazole, (1.039) l- {[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2- yl]methyl}-lH-l,2,4-triazol-5-yl thiocyanate, (1.040) l- {[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4- difluorophenyl)oxiran-2-yl]methyl} - 1 H- 1 ,2,4-triazol-5-yl thiocyanate, (1.041) l- { [rel(2R,3S)-3-(2- chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-lH-l,2,4-triazol-5-yl thiocyanate, (1.042) 2- [(2R,4R,5R)-l-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-l,2,4- triazole-3-thione, (1.043) 2-[(2R,4R,5S)-l-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]- 2,4-dihydro-3H-l,2,4-triazole-3-thione, (1.044) 2-[(2R,4S,5R)-l-(2,4-dichlorophenyl)-5-hydroxy-2,6,6- trimethylheptan-4-yl]-2,4-dihydro-3H-l,2,4-triazole-3-thione, (1.045) 2-[(2R,4S,5S)-l-(2,4- dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-l,2,4-triazole-3-thione, (1.046) 2-[(2S,4R,5R)-l-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-l,2,4- triazole-3 -thione, (1.047) 2-[(2S,4R,5S)-l-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]- 2,4-dihydro-3H-l,2,4-triazole-3-thione, (1.048) 2-[(2S,4S,5R)-l-(2,4-dichlorophenyl)-5-hydroxy-2,6,6- trimethylheptan-4-yl]-2,4-dihydro-3H-l,2,4-triazole-3-thione, (1.049) 2-[(2S,4S,5S)-l-(2,4- dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-l,2,4-triazole-3-thione, (1.050) 2-[l-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-l,2,4-triazole-3- thione, (1.051) 2-[2-chloro-4-(2,4-dichlorophenoxy)phenyl]-l-(lH-l,2,4-triazol-l-yl)propan-2-ol, (1.052) 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-l-(lH-l,2,4-triazol-l-yl)butan-2-ol, (1.053) 2-[4-(4- chlorophenoxy)-2-(trifluoromethyl)phenyl]-l -(lH-l,2,4-triazol-l -yl)butan-2-ol, (1.054) 2-[4-(4- chlorophenoxy)-2-(trifluoromethyl)phenyl]-l -(lH-l,2,4-triazol-l -yl)pentan-2-ol, (1.055)

Mefentrifluconazole, (1.056) 2- {[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4- dihydro-3H-l,2,4-triazole-3-thione, (1.057) 2- {[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4- difluorophenyl)oxiran-2-yl]methyl} -2,4-dihydro-3H-l,2,4-triazole-3-thione, (1.058) 2- {[rel(2R,3S)-3-(2- chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3H-l,2,4-triazole-3-thione,

(1.059) 5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-l-(lH-l,2,4-triazol-l-ylmethyl)cyclopentanol, (1.060) 5-(allylsulfanyl)- 1 - { [3 -(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl} - 1 H- 1 ,2,4- triazole, (1.061) 5-(allylsulfanyl)-l-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2- yl] methyl j - 1 H- 1 ,2,4-triazole, ( 1.062) 5-(allylsulfanyl)- 1 - { [rel(2R,3 S)-3-(2-chlorophenyl)-2-(2,4- difluorophenyl)oxiran-2-yl]methyl}-lH- 1,2, 4-triazole, (1.063) N'-(2,5-dimethyl-4-{[3-(l, 1,2,2- tetrafluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-metliylimidoformamide, (1.064) N'-(2,5-dimethyl- 4- {[3-(2,2,2-trifluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidoformamide, (1.065) N'- (2,5-dimethyl-4-{[3-(2,2,3,3-tetrafluoropropoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N- methylimidoformamide, (1.066) N'-(2,5-dimethyl-4- {[3-(pentafluoroethoxy)phenyl]sulfanyl}phenyl)-N- ethyl-N-methylimidoformamide, (1.067) N'-(2,5-dimethyl-4- {3-[(l, 1,2,2- tetrafluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (1.068) N'-(2,5-dimethyl- 4- {3-[(2,2,2-trifluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidoformamide, (1.069) N'- (2,5-dimethyl-4-{3-[(2,2,3,3-tetrafluoropropyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N- methylimidoformamide, (1.070) N'-(2,5-dimethyl-4- {3-[(pentafluoroethyl)sulfanyl]phenoxy}phenyl)-N- ethyl-N-methylimidoformamide, (1.071) N'-(2,5-dimethyl-4-phenoxyphenyl)-N-ethyl-N- methylimidoformamide, (1.072) N'-(4-{[3-(difluoromethoxy)phenyl]sulfanyl}-2,5-dimethylphenyl)-N- ethyl-N-methylimidoformamide, (1.073) N'-(4- {3-[(difluoromethyl)sulfanyl]phenoxy} -2,5- dimethylphenyl)-N-ethyl-N-methylimidoformamide, (1.074) N'-[5-bromo-6-(2,3-dihydro-lH-inden-2- yloxy)-2-methylpyridin-3 -yl] -N-ethyl-N-methylimidoformamide, (1.075) N'- {4- [(4,5-dichloro- 1,3- thiazol-2-yl)oxy]-2,5-dimethylphenyl} -N-ethyl-N-methylimidoformamide, (1.076) N'- {5-bromo-6-

[(lR)-l-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl} -N-ethyl-N-methylimidoformamide, (1.077) N'-{5-bromo-6-[(lS)-l -(3, 5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl} -N-ethyl-N- methylimidoformamide, (1.078) N'- {5-bromo-6-[(cis-4-isopropylcyclohexyl)oxy]-2-methylpyridin-3- yl} -N-ethyl-N-methylimidoformamide, (1.079) N'-{5-bromo-6-[(trans-4-isopropylcyclohexyl)oxy]-2- methylpyridin-3-yl} -N-ethyl-N-methylimidoformamide, (1.080) N'- {5-bromo-6-[l -(3,5- difluorophenyl)ethoxy]-2-methylpyridin-3-yl} -N-ethyl-N-methylimidoformamide, (1.081)

Ipfentrifluconazole, and (1.082) 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-l -(1 ,2,4-triazol- l-yl)propan-2-ol.

2) Inhibitors of the respiratory chain at complex I or II, for example (2.001) benzovindiflupyr, (2.002) bixafen, (2.003) boscalid, (2.004) carboxin, (2.005) fluopyram, (2.006) flutolanil, (2.007) fluxapyroxad, (2.008) furametpyr, (2.009) Isofetamid, (2.010) isopyrazam (anti-epimeric enantiomer lR,4S,9S), (2.011) isopyrazam (anti-epimeric enantiomer lS,4R,9R), (2.012) isopyrazam (anti-epimeric racemate lRS,4SR,9SR), (2.013) isopyrazam (mixture of syn-epimeric racemate lRS,4SR,9RS and anti-epimeric racemate lRS,4SR,9SR), (2.014) isopyrazam (syn-epimeric enantiomer lR,4S,9R), (2.015) isopyrazam (syn-epimeric enantiomer lS,4R,9S), (2.016) isopyrazam (syn-epimeric racemate lRS,4SR,9RS), (2.017) penflufen, (2.018) penthiopyrad, (2.019) pydiflumetofen, (2.020) Pyraziflumid, (2.021) sedaxane, (2.022) l,3-dimethyl-N-(l ,l,3-trimethyl-2,3-dihydro-lH-inden-4-yl)-lH-pyrazole-4-carboxamide, (2.023) 1,3- dimethyl-N-[(3R)-l,l,3-trimethyl-2,3-dihydro-lH-inden-4-yl]-lH-pyrazole-4-carboxamide, (2.024) 1,3- dimethyl-N-[(3S)-l,l,3-trimethyl-2,3-dihydro-lH-inden-4-yl]-lH-pyrazole-4-carboxamide, (2.025) 1- methyl-3-(trifluoromethyl)-N-[2'-(trifluoromethyl)biphenyl-2-yl]-lH-pyrazole-4-carboxamide, (2.026) 2-fluoro-6-(trifluoromethyl)-N-(l ,l,3-trimethyl-2,3-dihydro-lH-inden-4-yl)benzamide, (2.027) 3-

(difluoromethyl)- 1 -methyl-N-( 1 , 1 ,3 -trimethyl-2,3 -dihydro- 1 H-inden-4-yl)- 1 H-pyrazole-4-carboxamide, (2.028)inpyrfluxam, (2.029) 3-(difluoromethyl)-l -methyl-N-[(3S)-l,l,3-trimethyl-2,3-dihydro-lH- inden-4-yl]-lH-pyrazole-4-carboxamide, (2.030) Fluindapyr, (2.031) 3-(difluoromethyl)-N-[(3R)-7- fluoro-l,l,3-trimethyl-2,3-dihydro-lH-inden-4-yl]-l -methyl-lH-pyrazole-4-carboxamide, (2.032) 3-

(difluoromethyl)-N-[(3S)-7-fluoro-l,l,3-trimethyl-2,3-dihydro-lH-inden-4-yl]-l -methyl-lH-pyrazole-4- carboxamide, (2.033) 5,8-difluoro-N-[2-(2-fluoro-4- {[4-(trifluoromethyl)pyridin-2- yl]oxy}phenyl)ethyl]quinazolin-4-amine, (2.034) N-(2-cyclopentyl-5-fluorobenzyl)-N-cyclopropyl-3- (difluoromethyl)-5-fluoro-l -methyl- lH-pyrazole-4-carboxamide, (2.035) N-(2-tert-butyl-5- methylbenzyl)-N-cyclopropyl-3 -(difluoromethyl)-5-fluoro- 1 -methyl- 1 H-pyrazole-4-carboxamide, (2.036) N-(2-tert-butylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-l-methyl-lH-pyrazole-4- carboxamide, (2.037) N-(5-chloro-2-ethylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fhioro-l -methyl- lH-pyrazole-4-carboxamide, (2.038) N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)- 5-fluoro-l -methyl- lH-pyrazole-4-carboxamide, (2.039) N-[(1R, 4S)-9-(dichloromethylene)-l, 2,3,4- tetrahydro- 1 ,4-methanonaphthalen-5-yl] -3 -(difluoromethyl)- 1 -methyl- 1 H-pyrazole-4-carboxamide, (2.040) N-[(lS,4R)-9-(dichloromethylene)-l,2,3,4-tetrahydro-l,4-methanonaphthalen-5-yl]-3-

(difluoromethyl)- 1 -methyl- 1 H-pyrazole-4-carboxamide, (2.041 ) N- [ 1 -(2,4-dichlorophenyl)- 1 - methoxypropan-2-yl]-3-(difluoromethyl)-l-methyl-lH-pyrazole-4-carboxamide, (2.042) N-[2-chloro-6- (trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-l-methyl-lH-pyrazole-4- carboxamide, (2.043) N-[3-chloro-2-fluoro-6-(trifluoromethyl)benzyl]-N-cyclopropyl-3-

(difluoromethyl)-5-fluoro-l -methyl- lH-pyrazole-4-carboxamide, (2.044) N-[5-chloro-2-

(trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-l-methyl-lH-pyrazole-4- carboxamide, (2.045) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-l-methyl-N-[5-methyl-2-

(trifluoromethyl)benzyl]- 1 H-pyrazole-4-carboxamide, (2.046) N-cyclopropyl-3 -(difluoromethyl)-5- fluoro-N-(2-fluoro-6-isopropylbenzyl)-l -methyl- lH-pyrazole-4-carboxamide, (2.047) N-cyclopropyl-3- (difluoromethyl)-5-fluoro-N-(2-isopropyl-5-methylbenzyl)- 1 -methyl- 1 H-pyrazole-4-carboxamide, (2.048) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropylbenzyl)-l-methyl-lH-pyrazole-4- carbothioamide, (2.049) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropylbenzyl)-l -methyl- lH-pyrazole-4-carboxamide, (2.050) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(5-fluoro-2- isopropylbenzyl)-l -methyl- lH-pyrazole-4-carboxamide, (2.051) N-cyclopropyl-3-(difluoromethyl)-N- (2-ethyl-4,5-dimethylbenzyl)-5-fluoro-l-methyl-lH-pyrazole-4-carboxamide, (2.052) N-cyclopropyl-3- (difluoromethyl)-N-(2-ethyl-5-fluorobenzyl)-5-fluoro-l -methyl-lH-pyrazole-4-carboxamide, (2.053) N- cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-5-methylbenzyl)-5-fluoro-l-methyl-lH-pyrazole-4- carboxamide, (2.054) N-cyclopropyl-N-(2-cyclopropyl-5-fluorobenzyl)-3-(difluoromethyl)-5-fluoro-l- methyl-lH-pyrazole-4-carboxamide, (2.055) N-cyclopropyl-N-(2-cyclopropyl-5-methylbenzyl)-3- (difluoromethyl)-5-fluoro- 1 -methyl- 1 H-pyrazole-4-carboxamide, (2.056) N-cyclopropyl-N-(2- cyclopropylbenzyl)-3-(difluoromethyl)-5-fluoro-l-methyl-lH-pyrazole-4-carboxamide, (2.057) pyrapropoyne.

3) Inhibitors of the respiratory chain at complex III, for example (3.001) ametoctradin, (3.002) amisulbrom, (3.003) azoxystrobin, (3.004) coumethoxystrobin, (3.005) coumoxystrobin, (3.006) cyazofamid, (3.007) dimoxystrobin, (3.008) enoxastrobin, (3.009) famoxadone, (3.010) fenamidone, (3.011) flufenoxystrobin, (3.012) fluoxastrobin, (3.013) kresoxim-methyl, (3.014) metominostrobin, (3.015) orysastrobin, (3.016) picoxystrobin, (3.017) pyraclostrobin, (3.018) pyrametostrobin, (3.019) pyraoxystrobin, (3.020) trifloxystrobin, (3.021) (2E)-2-{2-[({[(lE)-l-(3-{[(E)-l-fluoro-2- phenylvinyl]oxy}phenyl)ethylidene]amino}oxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide, (3.022) (2E,3Z)-5-{[l-(4-chlorophenyl)-lH-pyrazol-3-yl]oxy}-2-(methoxyimino)-N,3-dimethylpent-3- enamide, (3.023) (2R)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide, (3.024) (2S)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide,

(3.025)fenpicoxamid, (3.026) mandestrobin, (3.027) N-(3-ethyl-3,5,5-trimethylcyclohexyl)-3- formamido-2-hydroxybenzamide, (3.028) (2E,3Z)-5-{[l-(4-chloro-2-fluorophenyl)-lH-pyrazol-3- yl]oxy}-2-(methoxyimino)-N,3-dimethylpent-3-enamide, (3.029) methyl {5-[3-(2,4-dimethylphenyl)- lH-pyrazol-l-yl]-2-methylbenzyl} carbamate, (3.030) metyltetraprole, (3.031) florylpicoxamid.

4) Inhibitors of the mitosis and cell division, for example (4.001) carbendazim, (4.002) diethofencarb,

(4.003) ethaboxam, (4.004) fluopicolide, (4.005) pencycuron, (4.006) thiabendazole, (4.007) thiophanate- methyl, (4.008) zoxamide, (4.009) 3-chloro-4-(2,6-difluorophenyl)-6-methyl-5-phenylpyridazine, (4.010) 3-chloro-5-(4-chlorophenyl)-4-(2,6-difluorophenyl)-6-methylpyridazine, (4.011) 3-chloro-5-(6- chloropyridin-3-yl)-6-methyl-4-(2,4,6-trifluorophenyl)pyridazine, (4.012) 4-(2-bromo-4-fluorophenyl)- N-(2,6-difluorophenyl)-l,3-dimethyl-lH-pyrazol-5-amine, (4.013) 4-(2-bromo-4-fluorophenyl)-N-(2- bromo-6-fluorophenyl)- 1 ,3-dimethyl- 1 H-pyrazol-5-amine, (4.014) 4-(2-bromo-4-fluorophenyl)-N-(2- bromophenyl)-l,3-dimethyl-lH-pyrazol-5-amine, (4.015) 4-(2-bromo-4-fluorophenyl)-N-(2-chloro-6- fluorophenyl)- 1 ,3-dimethyl- 1 H-pyrazol-5-amine, (4.016) 4-(2-bromo-4-fluorophenyl)-N-(2- chlorophenyl)-l,3-dimethyl-lH-pyrazol-5-amine, (4.017) 4-(2-bromo-4-fluorophenyl)-N-(2- fluorophenyl)-l,3-dimethyl-lH-pyrazol-5-amine, (4.018) 4-(2-chloro-4-fluorophenyl)-N-(2,6- difluorophenyl)-l,3-dimethyl-lH-pyrazol-5-amine, (4.019) 4-(2-chloro-4-fluorophenyl)-N-(2-chloro-6- fluorophenyl)-l,3-dimethyl-lH-pyrazol-5-amine, (4.020) 4-(2-chloro-4-fluorophenyl)-N-(2- chlorophenyl)- 1 ,3-dimethyl- 1 H-pyrazol-5-amine, (4.021 ) 4-(2-chloro-4-fluorophenyl)-N-(2- fluorophenyl)-l,3-dimethyl-lH-pyrazol-5-amine, (4.022) 4-(4-chlorophenyl)-5-(2,6-difluorophenyl)-3,6- dimethylpyridazine, (4.023) N-(2-bromo-6-fluorophenyl)-4-(2-chloro-4-fkiorophenyl)-l,3-dimethyl-lH- pyrazol-5-amine, (4.024) N-(2-bromophenyl)-4-(2-chloro-4-fluorophenyl)-l,3-dimethyl-lH-pyrazol-5- amine, (4.025) N-(4-chloro-2,6-difluorophenyl)-4-(2-chloro-4-fluorophenyl)-l,3-dimethyl-lH-pyrazol- 5-amine.

5) Compounds capable to have a multisite action, for example (5.001) bordeaux mixture, (5.002) captafol, (5.003) captan, (5.004) chlorothalonil, (5.005) copper hydroxide, (5.006) copper naphthenate, (5.007) copper oxide, (5.008) copper oxychloride, (5.009) copper(2+) sulfate, (5.010) dithianon, (5.011) dodine, (5.012) folpet, (5.013) mancozeb, (5.014) maneb, (5.015) metiram, (5.016) metiram zinc, (5.017) oxine- copper, (5.018) propineb, (5.019) sulfur and sulfur preparations including calcium polysulfide, (5.020) thiram, (5.021) zineb, (5.022) ziram, (5.023) 6-ethyl-5,7-dioxo-6,7-dihydro-5H- pyrrolo[3',4':5,6][l,4]dithiino[2,3-c] [l,2]thiazole-3-carbonitrile.

6) Compounds capable to induce a host defence, for example (6.001) acibenzolar-S-methyl, (6.002) isotianil, (6.003) probenazole, (6.004) tiadinil.

7) lnhibitors of the amino acid and/or protein biosynthesis, for example (7.001) cyprodinil, (7.002) kasugamycin, (7.003) kasugamycin hydrochloride hydrate, (7.004) oxytetracycline, (7.005) pyrimethanil, (7.006) 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-l-yl)quinoline.

8) lnhibitors of the ATP production, for example (8.001) silthiofam.

9) lnhibitors of the cell wall synthesis, for example (9.001) benthiavalicarb, (9.002) dimethomorph, (9.003) flumorph, (9.004) iprovalicarb, (9.005) mandipropamid, (9.006) pyrimorph, (9.007) valifenalate, (9.008) (2E)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-l -(morpholin-4-yl)prop-2-en-l-one, (9.009) (2Z)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-l-(morpholin-4-yl)prop-2-en-l -one.

10) lnhibitors of the lipid and membrane synthesis, for example (10.001) propamocarb, (10.002) propamocarb hydrochloride, (10.003) tolclofos-methyl.

11) lnhibitors of the melanin biosynthesis, for example (11.001) tricyclazole, (11.002) 2,2,2-trifluoroethyl {3-methyl-l-[(4-methylbenzoyl)amino]butan-2-yl}carbamate.

12) Inhibitors of the nucleic acid synthesis, for example (12.001) benalaxyl, (12.002) benalaxyl-M (kiralaxyl), (12.003) metalaxyl, (12.004) metalaxyl-M (mefenoxam).

13) Inhibitors of the signal transduction, for example (13.001) fludioxonil, (13.002) iprodione, (13.003) procymidone, (13.004) proquinazid, (13.005) quinoxyfen, (13.006) vinclozolin. 14) Compounds capable to act as an uncoupler, for example (14.001) fluazinam, (14.002) meptyldinocap.

15) Further compounds, for example (15.001) Abscisic acid, (15.002) benthiazole, (15.003) bethoxazin, (15.004) capsimycin, (15.005) carvone, (15.006) chinomethionat, (15.007) cufraneb, (15.008) cyflufenamid, (15.009) cymoxanil, (15.010) cyprosulfamide, (15.011) flutianil, (15.012) fosetyl- aluminium, (15.013) fosetyl-calcium, (15.014) fosetyl-sodium, (15.015) methyl isothiocyanate, (15.016) metrafenone, (15.017) mildiomycin, (15.018) natamycin, (15.019) nickel dimethyldithiocarbamate, (15.020) nitrothal-isopropyl, (15.021) oxamocarb, (15.022) Oxathiapiprolin, (15.023) oxyfenthiin, (15.024) pentachlorophenol and salts, (15.025) phosphorous acid and its salts, (15.026) propamocarb- fosetylate, (15.027) pyriofenone (chlazafenone), (15.028) tebufloquin, (15.029) tecloftalam, (15.030) tolnifanide, (15.031) l-(4- {4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-l,2-oxazol-3-yl]-l,3-thiazol-2- yl}piperidin-l -yl)-2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]ethanone, (15.032) l-(4- {4-[(5S)-5- (2,6-difluorophenyl)-4,5-dihydro-l,2-oxazol-3-yl]-l,3-thiazol-2-yl}piperidin-l-yl)-2-[5-methyl-3- (trifluoromethyl)-lH-pyrazol-l-yl]ethanone, (15.033) 2-(6-benzylpyridin-2-yl)quinazoline, (15.034) dipymetitrone, (15.035) 2-[3,5-bis(difluoromethyl)-lH-pyrazol-l-yl]-l -[4-(4- {5-[2-(prop-2-yn-l- yloxy)phenyl]-4,5-dihydro-l,2-oxazol-3-yl}-l,3-thiazol-2-yl)piperidin-l-yl]ethanone, (15.036) 2-[3,5- bis(difluoromethyl)-lH-pyrazol-l-yl]-l -[4-(4- {5-[2-chloro-6-(prop-2-yn-l-yloxy)phenyl]-4, 5-dihydro-

1.2-oxazol-3-yl}-l,3-thiazol-2-yl)piperidin-l-yl]ethanone, (15.037) 2-[3,5-bis(difluoromethyl)-lH- pyrazol-l-yl]-l-[4-(4- {5-[2-fluoro-6-(prop-2-yn-l-yloxy)phenyl]-4,5-dihydro-l,2-oxazol-3-yl}-l,3- thiazol-2-yl)piperidin-l-yl]ethanone, (15.038) 2-[6-(3-fluoro-4-methoxyphenyl)-5-methylpyridin-2- yl]quinazoline, (15.039) 2- {(5R)-3-[2-(l- {[3,5-bis(difluoromethyl)-lH-pyrazol-l-yl]acetyl}piperidin-4- yl)-l,3-thiazol-4-yl]-4,5-dihydro-l,2-oxazol-5-yl}-3-chlorophenyl methanesulfonate, (15.040) 2- {(5S)-3- [2-(l- {[3, 5-bis(difluoromethyl)-lH-pyrazol-l-yl]acetyl}piperidin-4-yl)-l,3-thiazol-4-yl]-4, 5-dihydro-

1.2-oxazol-5-yl}-3-chlorophenyl methanesulfonate, (15.041) Ipflufenoquin, (15.042) 2- {2-fluoro-6-[(8- fluoro-2-methylquinolin-3-yl)oxy]phenyl}propan-2-ol, (l5.043)fluoxapiprolin, (15.044) 2- {3-[2-(l- { [3,5-bis(difluoromethyl)- 1 H-pyrazol- 1 -yl]acetyl}piperidin-4-yl)- 1 ,3-thiazol-4-yl] -4,5-dihydro- 1 ,2- oxazol-5-yl}phenyl methanesulfonate, (15.045) 2-phenylphenol and salts, (15.046) 3-(4,4,5-trifluoro-3,3- dimethyl-3,4-dihydroisoquinolin-l-yl)quinoline, (15.047) quinofumelin, (15.048) 4-amino-5- fluoropyrimidin-2-ol (tautomeric form: 4-amino-5-fluoropyrimidin-2(lH)-one), (15.049) 4-oxo-4-[(2- phenylethyl)amino]butanoic acid, (15.050) 5-amino- 1, 3, 4-thiadiazole-2-thiol, (15.051) 5-chloro-N'- phenyl-N'-(prop-2-yn-l -yl)thiophene-2-sulfonohydrazide, (15.052) 5-fluoro-2-[(4- fluorobenzyl)oxy]pyrimidin-4-amine, (15.053) 5-fluoro-2-[(4-methylbenzyl)oxy]pyrimidin-4-amine, (15.054) 9-fluoro-2,2-dimethyl-5-(quinolin-3-yl)-2,3-dihydro-l,4-benzoxazepine, (15.055) but-3-yn-l -yl | 6-[( i [(Z)-( l -methyl- 1 H-tctrazol-5-yl)(phcnyl)mcthylcnc]amino | oxy)mcthyl]pyridin-2-yl j earbamate, (15.056) ethyl (2Z)-3-amino-2-cyano-3-phenylacrylate, (15.057) phenazine-l -carboxylic acid, (15.058) propyl 3,4,5-trihydroxybenzoate, (15.059) quinolin-8-ol, (15.060) quinolin-8-ol sulfate (2: 1), (15.061) tert-butyl {6-[({[(l-methyl-lH-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2- yl} carbamate, (15.062) 5-fluoro-4-imino-3 -methyl- 1 - [(4-methylphenyl)sulfonyl] -3 ,4-dihydropyrimidin- 2(lH)-one, (15.063) aminopyrifen, (15.064) (N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N- ethyl-N-methylimidoformamide), (15.065) (N'-(2-chloro-5-methyl-4-phenoxyphenyl)-N-ethyl-N- methylimidoformamide), (15.066) (2- {2-[(7,8-difluoro-2-methylquinolin-3-yl)oxy]-6- fluorophenyl}propan-2-ol), (15.067) (5-bromo-l-(5,6-dimethylpyridin-3-yl)-3,3-dimethyl-3,4- dihydroisoquinoline), (15.068) (3-(4,4-difluoro-5,5-dimethyl-4,5-dihydrothieno[2,3-c]pyridin-7- yl)quinoline), (15.069) (l-(4,5-dimethyl-lH-benzimidazol-l-yl)-4,4-difluoro-3,3-dimethyl-3,4- dihydroisoquinoline), (15.070) 8-fluoro-3-(5-fluoro-3,3-dimethyl-3,4-dihydroisoquinolin-l-yl)quinolone, (15.071) 8-fluoro-3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-l-yl)quinolone, (15.072) 3- (4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinolin-l-yl)-8-fluoroquinoline, (15.073) (N-methyl-N- phenyl-4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]benzamide), (15.074) (methyl{4-[5-

(trifluoromethyl)-l, 2, 4-oxadiazo 1-3 -yl]phenyl} carbamate), (15.075) (N- {4-[5-(trifluoromethyl)-l,2,4- oxadiazol-3-yl]benzyl}cyclopropanecarboxamide), (15.076) N-methyl-4-(5-(trifluoromethyl)- 1,2,4- oxadiazol-3-yl]benzamide, (15.077) N-[(E)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-l,2,4- oxadiazol-3-yl]benzamide, (15.078) N-[(Z)-methoxyiminomethyl]-4-[5-(trifluoromethyl)-l,2,4- oxadiazol-3-yl]benzamide, (15.079) N-[4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]phenyl]- cyclopropanecarboxamide, (15.080) N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3- yljbenzamide, (15.081) 2,2-difluoro-N-methyl-2-[4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]phenyl]- acetamide, (15.082) N-allyl-N-[[4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)phenyl]methyl]acetamide, (15.083) N-[(E)-N-methoxy-C-methyl-carbonimidoyl]-4-(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]- benzamide, (15.084) N-[(Z)-N-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-l,2,4- oxadiazol-3-yl]benzamide, (15.085) N-allyl-N-[[4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]phenyl]- methyljpropanamide, (15.086) 4,4-dimethyl-l-[[4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl]phenyl]methyl]pyrrolidin-2-one, (15.087) N-methyl-4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]- benzenecarbothioamide, (15.088) 5-methyl-l-[[4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl]phenyl]methyl]pyrrolidin-2-one, (15.089) N-((2,3-difluoro-4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl]phenyl]methyl]-3,3,3-trifluoro-propanamide, (15.090) l-methoxy-l-methyl-3-[[4-[5-

(trifluorometyhl) - 1 , 2, 4-oxadiazo l-3-yl]phenyl]methyl]urea, (15.091) 1,1 -diethyl-3 -[[4- [5-

(trifluoromethyl} -l,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.092) N-[[4-[5- (trifluoromethyl)- 1,2, 4-oxadiazo 1-3 -yl]phenyl)methyl)propanamide, (15.093) N-methoxy-N-[[4-[5-(trifluoromethyl)-l,2,4- oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, (15.094) l-methoxy-3-methyl-l-[[4-[5- (trifluoromethyl)- 1,2, 4-oxadiazo 1-3 -yl]phenyl]methyl]urea, (15.095) N-methoxy-N-[[4-[5-

(trifluoromethyl)-l,2,4-oxadiazol-3-yl]phenyl]methly)cyclopropanecarboxamide, (15.096) N,2- dimethoxy-N-[[4-[5-(trifluoromethyl}-l,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, (15.097) N- ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)phenyl]melhyl]propanamide, (15.098) 1- methoxy-3-methyl-l -[[4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.099) 1,3- dimethoxy-l-[[4-[5-(trifluoromehtyl)-l,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.100) 3-ethyl-l - methoxy-l-[[4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]phenyl]methyl]urea, (15.101) l-[[4-[5-

(trifluoromethyl)-l,2,4-oxadiazol-3-yl]phenyl]methyl]piperidin-2-one, (15.102) 4,4-dimethyl-2-[[4-(5- (trifluoromethyl)-l,2,4-oxadiazol-3-yl]phenyl]methyl]isooxazolidin-3-one, (15.103) 5,5-dimethyl-2-[[4- [5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one, (15.104) 3,3-dimethyl-l- [[4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]phenyl]methyl]piperidin-2-one, (15.105) l-[[3-fluoro-4-(5- (trifluoromelhyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyl]azepan-2-one, (15.106) 4,4-dimethyl-2-[[4-(5-

(trifluoromethyl)-l,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one and (15.107) 5,5-dimethyl- 2-[[4-[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one.

All named mixing partners of the classes (1) to (15) as described here above can be present in the form of the free compound and/or, if their functional groups enable this, an agriculturally acceptable salt thereof.

Isoflucypram may also be combined with one or more biological control agents.

Examples of biological control agents which may be combined with Isoflucypram are:

(A) Antibacterial agents selected from the group of:

(Al) bacteria, such as (Al .l) Bacillus subtilis, in particular strain QST713/AQ713 (available as

SERENADE OPTI or SERENADE ASO from Bayer CropScience LP, US, having NRRL Accession No. B21661and described in U.S. Patent No. 6,060,051); (A1.2) Bacillus amyloliquefaciens, in particular strain D747 (available as Double Nickel™ from Certis, US, having accession number FERM BP-8234 and disclosed in US Patent No. 7,094,592); (A1.3) Bacillus pumilus, in particular strain BU F- 33 (having NRRL Accession No. 50185); (A1.4) Bacillus subtilis var. amyloliquefaciens strain FZB24 (available as Taegro® from Novozymes, US); (A1.5) a Paenibacillus sp. strain having Accession No. NRRL B-50972 or Accession No. NRRL B-67129 and described in International Patent Publication No. WO 2016/154297; and

(A2) fungi, such as (A2.1) Aureobasidium pullulans, in particular blastospores of strain DSM14940; (A2.2) Aureobasidium pullulans blastospores of strain DSM 14941 ; (A2.3) Aureobasidium pullulans, in particular mixtures of blastospores of strains DSM14940 and DSM14941 ;

(B) Biological fungicides selected from the group of:

(Bl) bacteria, for example (Bl .l) Bacillus subtilis, in particular strain QST713/AQ713 (available as SERENADE OPTI or SERENADE ASO from Bayer CropScience LP, US, having NRRL Accession No. B2166 land described in U.S. Patent No. 6,060,051); (B1.2) Bacillus pumilus, in particular strain QST2808 (available as SONATA® from Bayer CropScience LP, US, having Accession No. NRRL B- 30087 and described in U.S. Patent No. 6,245,551); (B1.3) Bacillus pumilus, in particular strain GB34 (available as Yield Shield® from Bayer AG, DE); (B1.4) Bacillus pumilus, in particular strain BU F-33 (having NRRL Accession No. 50185); (B1.5) Bacillus amyloliquefaciens, in particular strain D747 (available as Double Nickel™ from Certis, US, having accession number FERM BP-8234 and disclosed in US Patent No. 7,094,592); (B1.6) Bacillus sublitis Y 1336 (available as BIOBAC^® WP from Bion-Tech, Taiwan, registered as a biological fungicide in Taiwan under Registration Nos. 4764, 5454, 5096 and 5277); (B1.7) Bacillus amyloliquefaciens strain MBI 600 (available as SUBTILEX from BASF SE); (B1.8) Bacillus subtilis strain GB03 (available as Kodiak® from Bayer AG, DE); (B1.9) Bacillus subtilis var. amyloliquefaciens strain FZB24 (available from Novozymes Biologicals Inc.,

Salem, Virginia or Syngenta Crop Protection, LLC, Greensboro, North Carolina as the fungicide TAEGRO^® or TAEGRO^® ECO (EPA Registration No. 70127-5); (B1.10) Bacillus mycoides, isolate J (available as BmJ TGAI or WG from Certis USA); (Bl . l l) Bacillus licheniformis, in particular strain SB3086 (available as EcoGuard TM Biofungicide and Green Releaf from Novozymes); (B1.12) a Paenibacillus sp. strain having Accession No. NRRL B-50972 or Accession No. NRRL B-67129 and described in International Patent Publication No. WO 2016/154297.

In some embodiments, the biological control agent is a Bacillus subtilis or Bacillus amyloliquefaciens strain that produces a fengycin or plipastatin-type compound, an iturin-type compound, and/or a surfactin- type compound. For background, see the following review article: Ongena, M., et al.,“Bacillus Lipopeptides: Versatile Weapons for Plant Disease Biocontrol,” Trends in Microbiology, Vol 16, No. 3, March 2008, pp. 115-125. Bacillus strains capable of producing lipopeptides include Bacillus subtilis QST713 (available as SERENADE OPTI or SERENADE ASO from Bayer CropScience LP, US, having NRRL Accession No. B2166 land described in U.S. Patent No. 6,060,051), Bacillus amyloliquefaciens strain D747 (available as Double Nickel™ from Certis, US, having accession number FERM BP-8234 and disclosed in US Patent No. 7,094,592); Bacillus subtilis MBI600 (available as SUBTILEX^® from Becker Underwood, US EPA Reg. No. 71840-8); Bacillus subtilis Y1336 (available as BIOBAC^® WP from Bion-Tech, Taiwan, registered as a biological fungicide in Taiwan under Registration Nos. 4764, 5454, 5096 and 5277); Bacillus amyloliquefaciens, in particular strain FZB42 (available as RHIZOVITAL^® from ABiTEP, DE); and Bacillus subtilis var. amyloliquefaciens FZB24 (available from Novozymes Biologicals Inc., Salem, Virginia or Syngenta Crop Protection, LLC, Greensboro, North Carolina as the fungicide TAEGRO^® or TAEGRO^® ECO (EPA Registration No. 70127-5); and

(B2) fungi, for example: (B2.1) Coniothyrium minitans, in particular strain CON/M/91-8 (Accession No. DSM-9660; e.g. Contans ® from Bayer); (B2.2) Metschnikowia fructicola, in particular strain NRRL Y- 30752 (e.g. Shemer®); (B2.3) Microsphaeropsis ochracea (e.g. Microx® from Prophyta); (B2.5) Trichoderma spp., including Trichoderma atroviride, strain SC1 described in International Application No. PCT/IT2008/000196); (B2.6) Trichoderma harzianum rifai strain KRL-AG2 (also known as strain T- 22, /ATCC 208479, e.g. PLANTSHIELD T-22G, Rootshield®, and TurfShield from Bio Works, US); (B2.14) Gliocladium roseum, strain 321U from W.F. Stoneman Company LLC; (B2.35) Talaromyces flavus, strain VI !7b; (B2.36) Trichoderma asperellum, strain ICC 012 from Isagro; (B2.37) Trichoderma asperellum, strain SKT-l (e.g. ECO-HOPE® from Kumiai Chemical Industry); (B2.38) Trichoderma atroviride, strain CNCM 1-1237 (e.g. Esquive® WP from Agrauxine, FR); (B2.39) Trichoderma atroviride, strain no. V08/002387; (B2.40) Trichoderma atroviride, strain NMI no. V08/002388; (B2.41) Trichoderma atroviride, strain NMI no. V08/002389; (B2.42) Trichoderma atroviride, strain NMI no. V08/002390; (B2.43) Trichoderma atroviride, strain LC52 (e.g. Tenet by Agrimm Technologies Limited); (B2.44) Trichoderma atroviride, strain ATCC 20476 (IMI 206040); (B2.45) Trichoderma atroviride, strain Tl l (IMI352941/ CECT20498); (B2.46) Trichoderma harmatum, (B2.47) Trichoderma harzianum, (B2.48) Trichoderma harzianum rifai T39 (e.g. Trichodex® from Makhteshim, US); (B2.49) Trichoderma harzianum, in particular, strain KD (e.g. Trichoplus from Biological Control Products, SA (acquired by Becker Underwood)); (B2.50) Trichoderma harzianum, strain ITEM 908 (e.g. Trianum-P from Koppert); (B2.51) Trichoderma harzianum, strain TH35 (e.g. Root-Pro by Mycontrol); (B2.52) Trichoderma virens (also known as Gliocladium virens), in particular strain GL-21 (e.g. SoilGard 12G by Certis, US); (B2.53) Trichoderma viride, strain TVl(e.g. Trianum-P by Koppert); (B2.54) Ampelomyces quisqualis, in particular strain AQ 10 (e.g. AQ 10® by IntrachemBio Italia); (B2.56) Aureobasidium pullulans, in particular blastospores of strain DSM14940; (B2.57) Aureobasidium pullulans, in particular blastospores of strain DSM 14941; (B2.58) Aureobasidium pullulans, in particular mixtures of blastospores of strains DSM14940 and DSM 14941 (e.g. Botector® by bio-ferm, CH); (B2.64) Cladosporium cladosporioides, strain H39 (by Stichting Dienst Landbouwkundig Onderzoek); (B2.69) Gliocladium catenulatum (Synonym: Clonostachys rosea f catenulate ) strain J1446 (e.g. Prestop ® by AgBio Inc. and also e.g. Primastop® by Kemira Agro Oy); (B2.70) Lecanicillium lecanii (formerly known as Verticillium lecanii ) conidia of strain KV01 (e.g. Vertalec® by Koppert/Arysta); (B2.71) Penicillium vermiculatum ; (B2.72) Pichia anomala, strain WRL-076 (NRRL Y-30842); (B2.75) Trichoderma atroviride, strain SKT-l (FERM P-16510); (B2.76) Trichoderma atroviride, strain SKT-2 (FERM P-16511); (B2.77) Trichoderma atroviride, strain SKT-3 (FERM P-17021); (B2.78) Trichoderma gamsii (formerly T. viride), strain ICC080 (IMI CC 392151 CABI, e.g. BioDermaby AGROBIOSOL DE MEXICO, S.A. DE C.V.); (B2.79) Trichoderma harzianum, strain DB 103 (e.g., T-Gro 7456 by Dagutat Biolab); (B2.80) Trichoderma polysporum, strain IMI 206039 (e.g. Binab TF WP by BINAB Bio-Innovation AB, Sweden); (B2.81) Trichoderma stromaticum (e.g. Tricovab by Ceplac, Brazil); (B2.83) Ulocladium oudemansii, in particular strain HRU3 (e.g. Botry-Zen® by Botry-Zen Ltd, NZ); (B2.84) Verticillium albo-atrum (formerly V. dahliae), strain WCS850 (CBS 276.92; e.g. Dutch Trig by Tree Care Innovations); (B2.86) Verticillium chlamydosporium; (B2.87) mixtures of Trichoderma asperellum strain ICC 012 and Trichoderma gamsii strain ICC 080 (product known as e.g. BIO-TAM™ from Bayer CropScience LP, US).

Further examples of biological control agents which may be combined with Isoflucypram are: bacteria selected from the group consisting of Bacillus cereus, in particular B. cereus strain CNCM 1-1562 and Bacillus firmus, strain 1-1582 (Accession number CNCM 1-1582), Bacillus subtilis strain OST 30002 (Accession No. NRRL B-50421), Bacillus thuringiensis, in particular B. thuringiensis subspecies israelensis (serotype H-14), strain AM65-52 (Accession No. ATCC 1276), B. thuringiensis subsp. aizawai, in particular strain ABTS-1857 (SD-1372), B. thuringiensis subsp. kurstaki strain HD-l, B. thuringiensis subsp. tenebrionis strain NB 176 (SD-5428), Pasteuria penetrans, Pasteuria spp. (Rotylenchulus reniformis nematode)-PR3 (Accession Number ATCC SD-5834), Streptomyces micrqflavus strain AQ6121 (= QRD 31.013, NRRL B-50550), and Streptomyces galbus strain AQ 6047 (Acession Number NRRL 30232); fungi and yeasts selected from the group consisting of Beauveria bassiana, in particular strain ATCC 74040, Lecanicillium spp., in particular strain HRO LEC 12, Metarhizium anisopliae, in particular strain F52 (DSM3884 or ATCC 90448), Paecilomyces fumosoroseus (how: Isaria fumosorosea), in particular strain 1FPC 200613, or strain Apopka 97 (Accesion No. ATCC 20874), and Paecilomyces lilacinus, in particular P. lilacinus strain 251 (AGAL 89/030550); viruses selected from the group consisting of Adoxophyes orana (summer fruit tortrix) granulosis virus (GV), Cydia pomonella (codling moth) granulosis virus (GV), Helicoverpa armigera (cotton bollworm) nuclear polyhedrosis virus (NPV), Spodoptera exigua (beet armyworm) mNPV, Spodoptera frugiperda (fall armyworm) mNPV, and Spodoptera littoralis (African cotton leafworm) NPV. bacteria and fungi which can be added as 'inoculant' to plants or plant parts or plant organs and which, by virtue of their particular properties, promote plant growth and plant health. Examples are: Agrobacterium spp., Azorhizobium caulinodans, Azospirillum spp., Azotobacter spp., Bradyrhizobium spp., Burkholderia spp., in particular Burkholderia cepacia (formerly known as Pseudomonas cepacia), Gigaspora spp., or Gigaspora monosporum, Glomus spp., Laccaria spp., Lactobacillus buchneri, Paraglomus spp., Pisolithus tinctorus, Pseudomonas spp., Rhizobium spp., in particular Rhizobium trifolii, Rhizopogon spp., Scleroderma spp., Suillus spp., and Streptomyces spp. plant extracts and products formed by microorganisms including proteins and secondary metabolites which can be used as biological control agents, such as Allium sativum, Artemisia absinthium, azadirachtin, Biokeeper WP, Cassia nigricans, Celastrus angulatus, Chenopodium anthelminticum, chitin, Armour-Zen, Dryopteris filix-mas, Equisetum arvense, Fortune Aza, Fungastop, Heads Up ( Chenopodium quinoa saponin extract), Pyrethrum/Pyrethrins , Quassia amara, Quercus, Quillaja, Regalia, "Requiem™ lnsecticide", rotenone, m/ ryanodinc, Symphytum officinale, Tanacetum vulgare, thymol, Triact 70, TriCon, Tropaeulum majus, Urtica dioica, Veratrin, Viscum album, Brassicaceae extract, in particular oilseed rape powder or mustard powder.

Examples of insecticides, acaricides and nematicides, respectively, which could be mixed with lsoflucypram are: (1) Acetylcholinesterase (AChE) inhibitors, such as, for example, carbamates, for example alanycarb, aldicarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, ethiofencarb, fenobucarb, formetanate, furathiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, triazamate, trimethacarb, XMC and xylylcarb; or organophosphates, for example acephate, azamethiphos, azinphos-ethyl, azinphos-methyl, cadusafos, chlorethoxyfos, chlorfenvinphos, chlormephos, chlorpyrifos-methyl, coumaphos, cyanophos, demeton-S -methyl, diazinon, dichlorvos/DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfoton, EPN, ethion, ethoprophos, famphur, fenamiphos, fenitrothion, fenthion, fosthiazate, heptenophos, imicyafos, isofenphos, isopropyl O-(methoxyaminothiophosphoryl) salicylate, isoxathion, malathion, mecarbam, methamidophos, methidathion, mevinphos, monocrotophos, naled, omethoate, oxydemeton-methyl, parathion-methyl, phenthoate, phorate, phosalone, phosmet, phosphamidon, phoxim, pirimiphos-methyl, profenofos, propetamphos, prothiofos, pyraclofos, pyridaphenthion, quinalphos, sulfotep, tebupirimfos, temephos, terbufos, tetrachlorvinphos, thiometon, triazophos, triclorfon and vamidothion.

(2) GABA-gated chloride channel blockers, such as, for example, cyclodiene-organochlorines, for example chlordane and endosulfan or phenylpyrazoles (fiproles), for example ethiprole and fipronil.

(3) Sodium channel modulators, such as, for example, pyrethroids, e.g. acrinathrin, allethrin, d-cis-trans allethrin, d-trans allethrin, bifenthrin, bioallethrin, bioallethrin s-cyclopentenyl isomer, bioresmethrin, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin, cyphenothrin [(lR)-trans-isomer], deltamethrin, empenthrin [(EZ)-(lR)-isomer], esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucythrinate, flumethrin, tau-fluvalinate, halfenprox, imiprothrin, kadethrin, momfluorothrin, permethrin, phenothrin [(lR)-trans-isomer], prallethrin, pyrethrins (pyrethrum), resmethrin, silafluofen, tefluthrin, tetramethrin, tetramethrin [(1R)- isomer)], tralomethrin and transfluthrin or DDT or methoxychlor.

(4) Nicotinic acetylcholine receptor (nAChR) competitive modulators, such as, for example, neonicotinoids, e.g. acetamiprid, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid and thiamethoxam or nicotine or sulfoxaflor or flupyradifurone.

(5) Nicotinic acetylcholine receptor (nAChR) allosteric modulators, such as, for example, spinosyns, e.g. spinetoram and spinosad.

(6) Glutamate-gated chloride channel (GluCl) allosteric modulators, such as, for example, avermectins/milbemycins, for example abamectin, emamectin benzoate, lepimectin and milbemectin. (7) Juvenile hormone mimics, such as, for example, juvenile hormone analogues, e.g. hydroprene, kinoprene and methoprene or fenoxycarb or pyriproxyfen.

(8) Miscellaneous non-specific (multi-site) inhibitors, such as, for example, alkyl halides, e.g. methyl bromide and other alkyl halides; or chloropicrine or sulphuryl fluoride or borax or tartar emetic or methyl isocyanate generators, e.g. diazomet and metam.

(9) Modulators of Chordotonal Organs, such as, for example pymetrozine or flonicamid.

(10) Mite growth inhibitors, such as, for example clofentezine, hexythiazox and diflovidazin or etoxazole.

(11) Microbial disruptors of the insect gut membrane, such as, for example Bacillus thuringiensis subspecies israelensis, Bacillus sphaericus, Bacillus thuringiensis subspecies aizawai, Bacillus thuringiensis subspecies kurstaki, Bacillus thuringiensis subspecies tenebrionis, and B.t. plant proteins: CrylAb, CrylAc, CrylFa, CrylA.l05, Cry2Ab, Vip3A, mCry3A, Cry3Ab, Cry3Bb, Cry34Abl/35Abl.

(12) Inhibitors of mitochondrial ATP synthase, such as, ATP disruptors such as, for example, diafenthiuron or organotin compounds, for example azocyclotin, cyhexatin and fenbutatin oxide or propargite or tetradifon. (13) Uncouplers of oxidative phosphorylation via disruption of the proton gradient, such as, for example, chlorfenapyr, DNOC and sulfluramid.

(14) Nicotinic acetylcholine receptor channel blockers, such as, for example, bensultap, cartap hydrochloride, thiocylam, and thiosultap-sodium.

(15) Inhibitors of chitin biosynthesis, type 0, such as, for example, bistrifluron, chlorfluazuron, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, teflubenzuron and triflumuron.

(16) Inhibitors of chitin biosynthesis, type 1, for example buprofezin.

(17) Moulting disruptor (in particular for Diptera, i.e. dipterans), such as, for example, cyromazine.

(18) Ecdysone receptor agonists, such as, for example, chromafenozide, halofenozide, methoxyfenozide and tebufenozide.

(19) Octopamine receptor agonists, such as, for example, amitraz.

(20) Mitochondrial complex III electron transport inhibitors, such as, for example, hydramethylnone or acequinocyl or fluacrypyrim. (21) Mitochondrial complex I electron transport inhibitors, such as, for example from the group of the METI acaricides, e.g. fenazaquin, fenpyroximate, pyrimidifen, pyridaben, tebufenpyrad and tolfenpyrad or rotenone (Derris).

(22) Voltage-dependent sodium channel blockers, such as, for example indoxacarb or metaflumizone.

(23) Inhibitors of acetyl CoA carboxylase, such as, for example, tetronic and tetramic acid derivatives, e.g. spirodiclofen, spiromesifen and spirotetramat.

(24) Mitochondrial complex IV electron transport inhibitors, such as, for example, phosphines, e.g. aluminium phosphide, calcium phosphide, phosphine and zinc phosphide or cyanides, e.g. calcium cyanide, potassium cyanide and sodium cyanide.

(25) Mitochondrial complex II electron transport inhibitors, such as, for example, Z>e/a-ketonitrile derivatives, e.g. cyenopyrafen and cyflumetofen and carboxanilides, such as, for example, pyflubumide.

(28) Ryanodine receptor modulators, such as, for example, diamides, e.g. chlorantraniliprole, cyantraniliprole and flubendiamide, further active compounds such as, for example, Afidopyropen, Afoxolaner, Azadirachtin, Benclothiaz, Benzoximate, Bifenazate, Broflanilide, Bromopropylate, Chinomethionat, Chloroprallethrin, Cryolite, Cyclaniliprole, Cycloxaprid, Cyhalodiamide, Dicloromezotiaz, Dicofol, epsilon-Metofluthrin, epsilon- Momfluthrin, Flometoquin, Fluazaindolizine, Fluensulfone, Flufenerim, Flufenoxystrobin, Flufiprole, Fluhexafon, Fluopyram, Fluralaner, Fluxametamide, Fufenozide, Guadipyr, Heptafluthrin, Imidaclothiz, Iprodione, kappa-Bifenthrin, kappa-Tefluthrin, Lotilaner, Meperfluthrin, Paichongding, Pyridalyl, Pyrifluquinazon, Pyriminostrobin, Spirobudiclofen, Tetramethylfluthrin, Tetraniliprole, Tetrachlorantraniliprole, Tigolaner, Tioxazafen, Thiofluoximate, Triflumezopyrim and iodomethane; furthermore preparations based on Bacillus firmus (1-1582, BioNeem, Votivo), and also the following compounds: l-{2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulphinyl]phenyl}-3-(trifluoromethyl)-lH- l,2,4-triazole-5-amine (known from W02006/043635) (CAS 885026-50-6), {l'-[(2E)-3-(4- chlorophenyl)prop-2-en-l-yl]-5-fluorospiro[indol-3,4'-piperidin]-l(2H)-yl}(2-chloropyridin-4- yl)methanone (known from W02003/106457) (CAS 637360-23-7), 2-chloro-N-[2-{l-[(2E)-3-(4- chlorophenyl)prop-2-en- 1 -yl]piperidin-4-yl} -4-(trifluoromethyl)phenyl]isonicotinamide (known from W02006/003494) (CAS 872999-66-1), 3-(4-chloro-2,6-dimethylphenyl)-4-hydroxy-8-methoxy-l,8- diazaspiro[4.5]dec-3-en-2-one (known from WO 2010052161) (CAS 1225292-17-0), 3-(4-chloro-2,6- dimethylphenyl)-8-methoxy-2-oxo-l,8-diazaspiro[4.5]dec-3-en-4-yl ethyl carbonate (known from EP2647626) (CAS 1440516-42-6) , 4-(but-2-yn-l-yloxy)-6-(3,5-dimethylpiperidin-l-yl)-5- fluoropyrimidine (known from W02004/099160) (CAS 792914-58-0), PF1364 (known from

JP2010/018586) (CAS 1204776-60-2), N-[(2E)-l-[(6-chloropyridin-3-yl)methyl]pyridin-2(lH)- ylidene]-2,2,2-trifluorc> acetamide (known from WO2012/029672) (CAS 1363400-41-2), (3£)-3-[ l -[(6- chloro-3-pyridyl)methyl]-2-pyridylidene]-l,l,l-trifluoro-propan-2-one (known from WO2013/144213) (CAS 1461743-15-6), , A-[3-(benzylcarbamoyl)-4-chlorophenyl]-l -methyl-3-(pentafluoroethyl)-4-

(triffuommcthyl)- 1 //-pyrazolc-5-carboxamidc (known from W02010/051926) (CAS 1226889-14-0), 5- bromo-4-chloro-A-[4-chloro-2-methyl-6-(methylcarbamoyl)phenyl]-2-(3-chloro-2-pyridyl)pyrazole-3- carboxamide (known from CN103232431) (CAS 1449220-44-3), 4-[5-(3,5-dichlorophenyl)-4,5-dihydro- 5-(trifluoromethyl)-3-isoxazolyl]-2-methyl-A-(cA-l-oxido-3-thietanyl)-benzamide, 4-[5-(3,5- dichlorophcnyl)-4,5-dihydiO-5-(triffuoiOmcthyl)-3-isoxazolyl]-2-mcthyl-,V-(/ra/is- 1 -oxido-3-thictanyl)- benzamide and 4-[(55)-5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-2-methyl- N-(cis- 1 -oxido-3 -thietanyl)benzamide (known from WO 2013/050317 Al) (CAS 1332628-83-7), /V-[3-chlom- 1 -(3-pyridinyl)- 1 //-pyrazol-4-yl]-/V- ethyl-3 - [(3 ,3 ,3 -trifluoropropyl)sulfinyl] -propanamide, (+)-/V- [3 -chloro- 1 -(3 -pyridiny 1 )- 1 /7-pyrazol-4-yl] -A-ethyl-3 - [(3 ,3 ,3 -trifluoropropyl)sulfinyl] -propanamide and (-)-JV- [3 -chloro- 1 -(3 -pyridiny 1 )- 1 H- pyrazol-4-yl] -A-ethyl-3 - [(3 ,3 ,3 -trifluoropropyl)sulfinyl] -propanamide (known from

WO 2013/162715 A2, WO 2013/162716 A2, US 2014/0213448 Al) (CAS 1477923-37-7), 5-[[(2£)-3- chloro-2-propen-l-yl]amino]-l-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]- 1 //-pyrazolc-3-carbonitrilc (known from CN 101337937 A) (CAS 1105672-77-2), 3 - b ro m o - N- [4-chloro- 2-mcthyl-6-[(mcthylamino)thioxomcthyl]phcnyl]- 1 -(3-chlom-2-pyridinyl)- 1 //-pyrazolc-5 -carboxamide, (Liudaibenjiaxuanan, known from CN 103109816 A) (CAS 1232543-85-9); A-[4-chloro-2-[[(l,l- dimethylethyl)amino]carbonyl]-6-methylphenyl]-l-(3-chloro-2-pyridinyl)-3-(fluoromethoxy)-lT/- Pyrazole-5-carboxamide (known from WO 2012/034403 Al) (CAS 1268277-22-0), ,V-[2-(5-amino- 1 ,3, 4-thiadiazol-2-yl)-4-chloro-6-methylphenyl]-3-bromo-l-(3-chloro-2-pyridinyl)-lT/-pyrazole-5- carboxamide (known from WO 2011/085575 Al) (CAS 1233882-22-8), 4-[3-[2,6-dichloro-4-[(3,3- dichloro-2-propen-l-yl)oxy]phenoxy]propoxy]-2-methoxy-6-(trifluoromethyl)-pyrimidine (known from CN 101337940 A) (CAS 1108184-52-6); (2 E)- and 2(Z)-2-[2-(4-cyanophenyl)-l-[3-(trifluoromethyl) phenyl] ethylidene] -N- [4-(difluoromethoxy)phenyl] -hydrazinecarboxamide (known from

CN 101715774 A) (CAS 1232543-85-9); 3-(2,2-dichlorocthcnyl)-2,2-dimcthyl-4-( 1 //-bcnzimidazol-2- yl)phenyl-cyclopropanecarboxylic acid ester (known from CN 103524422 A) (CAS 1542271-46-4); (4a5) -7-chloro-2,5-dihydro-2-[[(methoxycarbonyl)[4-[(trifluoromethyl)thio]phenyl]amino]carbonyl]- indcno[ 1 ,2-r] [ 1 ,3,4]oxadiazinc-4a(3//)-carboxylic acid methyl ester (known from CN 102391261 A) (CAS 1370358-69-2); 6-deoxy-3-0-ethyl-2,4-di-0-methyl-, 1 -[/V-[4-[ 1 -[4-( 1 , 1 ,2,2,2-pcntaffuomcthoxy) phenyl]- 1 H- 1 ,2,4-triazol-3-yl]phcnyl]carbamatc]-a-L-mannopyranosc (known from

US 2014/0275503 Al) (CAS 1181213-14-8); 8-(2-cyclopropylmethoxy-4-trifluoromethyl-phenoxy)-3- (6-trifluoromethyl-pyridazin-3-yl)-3-aza-bicyclo[3.2.l ]octane (CAS 1253850-56-4), (H-ahίί)-H-(2- cyclopropylmethoxy-4-trifluoromethyl-phenoxy)-3-(6-trifluoromethyl-pyridazin-3-yl)-3-aza- bicyclo[3.2. l ]octane (CAS 933798-27-7), (8-yyn)-8-(2-cyclopropylmethoxy-4-trifluoromethyl-phenoxy) -3-(6-trifluoromethyl-pyridazin-3-yl)-3-aza-bicyclo[3.2. l ]octane (known from WO 2007040280 Al, WO 2007040282 Al) (CAS 934001-66-8), N-[3-chloro-l-(3-pyridinyl)-lH-pyrazol-4-yl]-N-ethyl-3- [(3,3,3-trifluoropropyl)thio]-propanamide (known from WO 2015/058021 Al, WO 2015/058028 Al) (CAS 1477919-27-9) and N-[4-(aminothioxomethyl)-2-methyl-6-[(methylamino)carbonyl]phenyl]-3- bromo- 1 -(3-chloro-2-pyridinyl)- 1 //-pyrazolc-5-carboxamidc (known from CN 103265527 A) (CAS 1452877-50-7), 5-(l,3-dioxan-2-yl)-4-[[4-(trifluoromethyl)phenyl]methoxy]-pyrimidine (known from WO 2013/115391 Al) (CAS 1449021-97-9), 3-(4-chloro-2,6-dimethylphenyl)-4-hydroxy-8-methoxy-l- methyl-l,8-diazaspiro[4.5]dec-3-en-2-one (known from WO 2010/066780 Al, WO 2011/151146 Al) (CAS 1229023-34-0), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-l-methyl-l,8-diazaspiro[4.5]decane- 2,4-dione (known from WO 2014/187846 Al) (CAS 1638765-58-8), 3-(4-chloro-2,6-dimethylphenyl)-8- methoxy-l-methyl-2-oxo-l,8-diazaspiro[4.5]dec-3-en-4-yl-carbonic acid ethyl ester (known from WO 2010/066780 Al, WO 2011151146 Al) (CAS 1229023-00-0), N-[l-[(6-chloro-3-pyridinyl)methyl]- 2( 1 //)-pyridinylidcnc]-2,2,2-trifluoro-acctamidc (known from DE 3639877 Al, WO 2012029672 Al) (CAS 1363400-41-2), [N(£)]-N-[ l -[(6-chloro-3 -pyridinyl (methyl] -2( 1 H)-pyridinylidcnc]-2,2,2-trifluoro- acetamide, (known from WO 2016005276 Al) (CAS 1689566-03-7), [N(Z)]-N-[l-[(6-chloro-3- pyridinyl)methyl]-2(lH)-pyridinylidene]-2,2,2-trifluoro-acetamide, (CAS 1702305-40-5), 3-endo-3-[2- propoxy-4-(trifluoromethyl)phenoxy]-9-[[5-(trifluoromethyl)-2-pyridinyl]oxy]-9- azabicyclo [3.3.1 ]nonane (known from WO 2011/105506 Al, WO 2016/133011 Al) (CAS 1332838-17- 1).

Examples of safeners which could be mixed with Isoflucypram are, for example, benoxacor, cloquintocet (-mexyl), cyometrinil, cyprosulfamide, dichlormid, fenchlorazole (-ethyl), fenclorim, flurazole, fluxofenim, furilazole, isoxadifen (-ethyl), mefenpyr

(-diethyl), naphthalic anhydride, oxabetrinil, 2-methoxy-N-({4-[(methylcarbamoyl)amino]phenyl} - sulphonyl)benzamide (CAS 129531-12-0), 4-(dichloroacetyl)-l-oxa-4-azaspiro[4.5]decane (CAS 71526- 07-3), 2,2,5-trimethyl-3-(dichloroacetyl)-l,3-oxazolidine (CAS 52836-31-4).

Examples of herbicides which could be mixed with Isoflucypram are:

Acetochlor, acifluorfen, acifluorfen-sodium, aclonifen, alachlor, allidochlor, alloxydim, alloxydim- sodium, ametryn, amicarbazone, amidochlor, amidosulfuron, 4-amino-3-chloro-5-fluoro-6-(7-fluoro-lE[- indol-6-yl)pyridine-2-carboxylic acid, aminocyclopyrachlor, aminocyclopyrachlor-potassium, aminocyclopyrachlor-methyl, aminopyralid, amitrole, ammoniumsulfamate, anilofos, asulam, atrazine, azafenidin, azimsulfuron, beflubutamid, benazolin, benazolin-ethyl, benfluralin, benfuresate, bensulfuron, bensulfuron-methyl, bensulide, bentazone, benzobicyclon, benzofenap, bicyclopyron, bifenox, bilanafos, bilanafos-sodium, bispyribac, bispyribac-sodium, bixlozone, bromacil, bromobutide, bromofenoxim, bromoxynil, bromoxynil-butyrate, -potassium, -heptanoate, and -octanoate, busoxinone, butachlor, butafenacil, butamifos, butenachlor, butralin, butroxydim, butylate, cafenstrole, carbetamide, carfentrazone, carfentrazone- ethyl, chloramben, chlorbromuron, l- {2-chloro-3-[(3-cyclopropyl-5- hydroxy-l-methyl-lH-pyrazol-4-yl)carbonyl]-6-(trifluormethyl)phenyl}piperidin-2-on, 4- {2-chloro-3- [(3,5-dimethyl- 1 H-pyrazol- 1 -yl)methyl]-4-(methylsulfonyl)benzoyl} - 1 ,3-dimethyl- 1 H-pyrazol-5-yl- 1,3- dimethyl-lH-pyrazol-4-carboxylat, chlorfenac, chlorfenac-sodium, chlorfenprop, chlorflurenol, chlorflurenol-methyl, chloridazon, chlorimuron, chlorimuron- ethyl, 2-[2-chloro-4-(methylsulfonyl)-3- (morpholin-4ylmethyl)benzoyl}-3-hydroxycyclohex-2-en-l-on, 4- {2-chloro-4-(methylsulfonyl)-3- [(2,2,2-trifluorethoxy)methyl]benzoyl} - 1 -ethyl- 1 H-pyrazol-5-yl- 1 ,3-dimethyl- 1 H,pyrazol-4-carboxylat, chlorophthalim, chlorotoluron, chlorthal- dimethyl, 3-[5-chloro-4-(trifluormethyl)pyridine-2-yl]-4- hydroxy-l-methylimidazolidine-2-on, chlorsulfuron, cinidon, cinidon- ethyl, cinmethylin, cinosulfuron, clacyfos, clethodim, clodinafop, clodinafop-propargyl, clomazone, clomeprop, clopyralid, cloransulam, cloransulam-methyl, cumyluron, cyanamide, cyanazine, cycloate, cyclopyranil, cyclopyrimorate, cyclosulfamuron, cycloxydim, cyhalofop, cyhalofop-butyl, cyprazine, 2,4-D, 2,4-D-butotyl, -butyl, - dimethylammonium, -diolamin, -ethyl, -2-ethylhexyl, -isobutyl, -isooctyl, -isopropylammonium, - potassium, -triisopropanolammonium, and -trolamine, 2,4-DB, 2,4-DB-butyl, -dimethylammonium, - isooctyl, -potassium, and -sodium, daimuron (dymron), dalapon, dazomet, n-decanol, desmedipham, detosyl-pyrazolate (DTP), dicamba, dichlobenil, 2-(2,4-dichlorobenzyl)-4, 4-dimethyl- l,2-oxazolidin-3 - one, 2-(2,5-dichlorobenzyl)-4,4-dimethyl-l,2-oxazolidin-3-one, dichlorprop, dichlorprop-P, diclofop, diclofop-methyl, diclofop-P-methyl, diclosulam, difenzoquat, diflufenican, diflufenzopyr, diflufenzopyr- sodium, dimefuron, dimepiperate, dimethachlor, dimethametryn, dimethenamid, dimethenamid-P, 3- (2,6-dimethylphenyl)-6-[(2-hydroxy-6-oxocyclohex-l -en-l-yl)carbonyl]-l -methylchinazolin- 2,4(lH,3H)-dion, l,3-dimethyl-4-[2-(methylsulfonyl)-4-(trifluormethyl)benzoyl]-lH-pyrazol-5-yl-l,3- dimethyl-lH-pyrazol-4-nitrobenzoate, SYP-300, i.e. l-[7-fluoro-3-oxo-4-(prop-2-yn-l-yl)-3,4-dihydro- 2H-l,4-benzoxazin-6-yl]-3-propyl-2-thioxoimidazolidine-4,5-dione, 2,3,6-TBA, TCA (trichloroacetic acid), TCA-sodium, tebuthiuron, tefuryltrione, tembotrione, tepraloxydim, terbacil, terbucarb, terbumeton, terbuthylazin, terbutryn, tetflupyrolimet, thenylchlor, thiazopyr, thiencarbazone, thien- carbazone-methyl, thifensulfuron, thifensulfuron-methyl, thiobencarb, tiafenacil, tolpyralate, topra- mezone, tralkoxydim, triafamone, tri-allate, triasulfuron, triaziflam, tribenuron, tribenuron-methyl, triclopyr, trietazine, trifloxysulfuron, trifloxysulfuron-sodium, trifludimoxazin, trifluralin, triflusulfuron, triflusulfuron-methyl, tritosulfuron, urea sulfate, vemolate, XDE-848, ZJ-0862, i.e. 3,4-dichloro-N- {2- [(4, 6-dimethoxypyrimidin-2-yl)oxy]benzyl} aniline.

Examples for plant growth regulators are:

Acibenzolar, acibenzolar-S-methyl, 5-aminolevulinic acid, ancymidol, 6-benzylaminopurine, Brassinolid, catechine, chlormequat chloride, cloprop, cyclanilide, 3-(cycloprop-l-enyl) propionic acid, daminozide, dazomet, n-decanol, dikegulac, dikegulac-sodium, endothal, endothal-dipotassium, -disodium, and - mono(N,N-dimethylalkylammonium), ethephon, flumetralin, flurenol, flurenol-butyl, flurprimidol, forchlorfenuron, gibberellic acid, inabenfide, indol-3-acetic acid (IAA), 4-indol-3-ylbutyric acid, isoprothiolane, probenazole, jasmonic acid, maleic hydrazide, mepiquat chloride, l-methylcyclopropene, methyl jasmonate, 2-(l-naphthyl)acetamide, 1 -naphthylacetic acid, 2- naphthyloxyacetic acid, nitrophenolate-mixture, paclobutrazol, N-(2-phenylethyl)-beta-alanine, N-phenylphthalamic acid, prohexadione, prohexadione-calcium, prohydrojasmone, salicylic acid, strigolactone, tecnazene, thidiazuron, triacontanol, trinexapac, trinexapac-ethyl, tsitodef, uniconazole, uniconazole-P.

According to the invention, the expression “combination” stands for the various combinations of compounds (A) and (B), for example in a single“ready-mix” form, in a combined spray mixture composed from separate formulations of the single active compounds, such as a“tank-mix”, and in a combined use of the single active ingredients when applied in a sequential manner, i.e. one after the other within a reasonably short period, such as a few hours or days. Preferably the order of applying the compounds (A) and (B) is not essential for working the present invention.

In the combinations according to the invention the compounds (A) and (B) can be present in a broad range of effective weight ratio of A:B, for example in a range of 5000: 1 to 1 :5000, preferably in a weight ratio of 1000: 1 to 1:1000, more preferably in a weight ratio of 500:1 to 1:500, and most preferably in a weight ratio of 100:1 to 1:100.

Further ratios of A:B which can be used according to the present invention are: 95: 1 to 1 :95, 90: 1 to 1 :90, 85: 1 to 1:85, 80:1 to 1:80, 75:1 to 1:75, 70:1 to 1:70, 65:1 to 1:65, 60:1 to 1:60, 55:1 to 1:55, 50:1 to 1:50, 45:1 to 1:45, 40:1 to 1:40, 35:1 to 1:35, 30:1 to 1:30, 25:1 to 1:25, 20:1 to 1:20, 15:1 to 1:15, 10:1 to 1:10, 5:1 to 1:5, 4:1 to 1:4, 3:1 to 1:3, 2:1 to 1:2.

Further ratios of A:B which can be used according to the present invention are: 1000:1 to 1:1, 500:1 to 1:1, 250:1 to 1:1, 100:1 to 1:1, 95:1 to 1:1, 90:1 to 1:1, 85:1 to 1:1, 80:1 to 1:1, 75:1 to 1:1, 70:1 to 1:1, 65:1 to 1:1, 60:1 to 1:1, 55:1 to 1:1, 50:1 to 1:1, 45:1 to 1:1, 40:1 to 1:1, 35:1 to 1:1, 30:1 to 1:1, 25:1 to 1:1, 20:1 to 1:1, 15:1 to 1:1, 10:1 to 1:1, 5:1 to 1:1, 4:1 to 1:1, 3:1 to 1:1, 2:1 to 1:1.

Further ratios of A:B which can be used according to the present invention are: 1 : 1 to 1:1000, 1 : 1 to 1 :500, 1 : 1 to 1:250, 1:1 to 1:100, 1:1 to 1:95, 1:1 to 1:90, 1:1 to 1:85, 1:1 to 1:80, 1:1 to 1:75, 1:1 to 1:70, 1:1 to 1:65, 1:1 to 1:60, 1:1 to 1:55, 1:1 to 1:50, 1:1 to 1:45, 1:1 to 1:40, 1:1 to 1:35, 1:1 to 1:30, 1:1 to 1:25, 1:1 to 1:20, 1:1 to 1:15, 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:4, 1:1 to 1:3, 1:1 to 1:2.

In another embodiment Isoflucypram may be present in their commercially available formulations and in the use forms, prepared from these formulations, as a mixture with one or more active ingredients selected from the group of fluopyram, prothioconazole, tebuconazole, epoxiconazole, difenoconazole, fluquinconazole, fluxapyroxad, flutriafol, azoxystrobin, trifloxystrobin, fluoxastrobin, fludioxonil, ipfentrifluconazole, metalaxyl, mefenoxam, mefentrifluconazole, pyraclostrobin, pyrimethanil, chlorothalonil, spiroxamine, bixafen, penflufen, fluxapyroxad, boscabd, benzovindiflupyr, sedaxane, isopyrazam, metrafenone, broflanibde, imidacloprid, clothianidin, thiacloprid, thiamethoxam, rynaxapyr, cyazypyr, spirotetramate, spiromesifen, tetranibprole, flubendiamide, cyclanibprole, lambda-cyhalothrin, fluazinam, metyltetrapole.

Particularly preferred are Prothioconazole or Tebuconazole. In a particular embodiment, Isoflucypram is used as a mixture comprising Prothioconazole and/or Tebuconazole

In a particular embodiment, Isoflucypram is used as a mixture with Prothioconazole or Tebuconazole

The use of Isoflucypram as a mixture with Prothioconazole or Tebuconazole is effected preferably with a dosage between 0.001 and 1 kg of Isoflucypram /ha, between 0.01 and 3 kg of Prothioconazole or Tebuconazole /ha ; more preferably between 0.002 and 0.5 kg of Isoflucypram /ha, between 0.025 and 1 kg of Prothioconazole or Tebuconazole /ha ; more preferably between 0.005 and 0.4 kg of Isoflucypram /ha, between 25 and 400 g of Prothioconazole or tebuconazole/h ; even more preferably between 7 and 150g of Isoflucypram /ha, between 25 and 400 g of Prothioconazole or tebuconazole/h ; most preferably between 10 and 120 g of Isoflucypram /ha, between 40 and 400 g of Prothioconazole or tebuconazole/ha. A dosage of 15 to 100 g of Isoflucypram /ha and 60 to 300 g of Prothioconazole or tebuconazole/ha, more preferably 20 to 70 g of Isoflucypram /ha and 60 to 300 g of Prothioconazole or tebuconazole/ha, is also disclosed. In another embodiment the dosage is between 40 and 150 g of Isoflucypram /ha and 60 to 240 g of Prothioconazole or tebuconazole/ha ; preferably between 30 and 120 g of Isoflucypram /ha and 60 to 200 g of Prothioconazole or tebuconazole/ha ; more preferred between 25 and 100 g of Isoflucypram /ha and 60 to 180 g of Prothioconazole or tebuconazole/ha, mostly preferred between 20 and 90 g g of Isoflucypram /ha and 60 to 180 g of Prothioconazole or tebuconazole/ha,.

In another embodiment, Isoflucypram is used as a mixture with Prothioconazole and Tebuconazole.

The use of Isoflucypram as a mixture with Prothioconazole and Tebuconazole is effected preferably with a dosage between 0.001 and 1 kg of Isoflucypram /ha, between 0.01 and 3 kg of Prothioconazole/ha, between 0.01 and 3 kg of Tebuconazole /ha ; more preferably between 0.002 and 0.5 kg of Isoflucypram /ha, between 0.025 and 1 kg of Prothioconazole/ha, between 0.025 and 1 kg of Tebuconazole /ha ; more preferably between 0.005 and 0.4 kg of Isoflucypram /ha, between 25 and 400 g of Prothioconazole/ha, between 25 and 400 g of tebuconazole/h ; even more preferably between 7 and 150g of Isoflucypram /ha, between 25 and 400 g of Prothioconazole/ha, between 25 and 400 g of tebuconazole/h ; most preferably between 10 and 120 g of Isoflucypram /ha, between 40 and 400 g of Prothioconazole/ha, between 40 and 400 g of tebuconazole/ha.

A dosage of 15 to 100 g of Isoflucypram /ha, 60 to 300 g of Prothioconazole/ha and 60 to 300 g of tebuconazole/ha, more preferably 20 to 70 g of Isoflucypram /ha, 60 to 300 g of Prothioconazole/ha and 60 to 300 g of tebuconazole/ha, is also disclosed.

In another embodiment the dosage is between 40 and 150 g of Isoflucypram /ha, between 60 and 240 g of Prothioconazole/ha and between 60 and 240 g of or tebuconazole/ha ; preferably between 30 and 120 g of Isoflucypram /ha, between 60 and 200 g of Prothioconazole/ha and between 60 and 200 g of tebuconazole/ha ; more preferred between 25 and 100 g of Isoflucypram /ha, between 60 and 180 g of Prothioconazole/ha and between 60 and 180 g of tebuconazole/ha, mostly preferred between 20 and 90 g of Isoflucypram /ha, between 60 and 180 g of Prothioconazole/ha and between 60 and 180 g of tebuconazole/ha. In a particular embodiment, isoflucypram is used as a mixture comprising fluazinam and/or metyltetrapole.

In a particular embodiment, isoflucypram is used as a mixture with fluazinam or metyltetrapole.

The use of Isoflucypram as a mixture with fluazinam or metyltetrapole is effected preferably with a dosage between 0.001 and 1 kg of Isoflucypram /ha, between 0.01 and 3 kg of fluazinam or metyltetrapole /ha ; more preferably between 0.002 and 0.5 kg of Isoflucypram /ha, between 0.025 and 1 kg of fluazinam or metyltetrapole /ha ; more preferably between 0.005 and 0.4 kg of Isoflucypram /ha, between 25 and 400 g of fluazinam or metyltetrapole /h ; even more preferably between 7 and 150g of Isoflucypram /ha, between 25 and 400 g of fluazinam or metyltetrapole /h ; most preferably between 10 and 120 g of Isoflucypram /ha, between 40 and 400 g of fluazinam or metyltetrapole /ha. A dosage of 15 to 100 g of Isoflucypram /ha and 60 to 300 g of fluazinam or metyltetrapole /ha, more preferably 20 to 70 g of Isoflucypram /ha and 60 to 300 g of fluazinam or metyltetrapole /ha, is also disclosed.

In another embodiment the dosage is between 40 and 150 g of Isoflucypram /ha and 60 to 240 g of fluazinam or metyltetrapole /ha ; preferably between 30 and 120 g of Isoflucypram /ha and 60 to 200 g of fluazinam or metyltetrapole /ha ; more preferred between 25 and 100 g of Isoflucypram /ha and 60 to 180 g of fluazinam or metyltetrapole /ha, mostly preferred between 20 and 90 g g of Isoflucypram /ha and 60 to 180 g of fluazinam or metyltetrapole /ha,.

In a particular embodiment of the invention, isoflucypram is not employed in combination with fenpicoxamid.

In another particular embodiment of the invention, isoflucypram is not employed in a ternary combination with (B) fenpicoxamid and (C) one further compound selected from prothioconazole, fluopyram and tebuconazole.

In another particular embodiment of the invention, isoflucypram is not employed in a ternary combination with (B) prothioconazole and (C) one further compound selected from trifloxystrobin, tebuconazole, or fluopyram.

The example which follows serves to illustrate the invention, but without restricting it.

Example 1

In Canada, in 2017, a test plot was conducted with the spring wheat variety CTC Utmost. Isoflucypram, as well as market standards, were applied on July 7, 2017 according to table 1 by foliar application, between BBCH stage59 and 61. Assessment of sclerotia was done in fall 2017 96 days post application.

Table 1 Efficacy of Isoflucypram against Claviceps purpurea and reduction of sclerotia in wheat

ISY means Isoflucypram; PTZ means Prothioconazole ; TBZ means Tebuconazole

Claims

Claims:

1. Use of the fungicide Isoflucypram for the control of Claviceps purpurea and/or reduction of sclerotia of Claviceps purpurea in cereal plants.

2. Use according to Claim 1, wherein Isoflucypram is applied as a foliar treatment to cereal plants.

3. Use according to Claim 1, wherein Isoflucypram is applied as a foliar treatment to cereal plants on or after BBCH 50.

4. Use according to any one of claims 1 to 3, wherein Isoflucypram is applied as a foliar treatment at a rate of 2 to 500 g per hectare.

5. Use according to any one of claims 1 to 3, wherein Isoflucypram is applied as a foliar treatment at a rate of 10 to 120 g per hectare.

6. Use according to any one of Claims 1 to 5, wherein the cereal plant is wheat, barley, rye, triticale or durum.

7. Use according to any one of Claims 1 to 6, wherein the cereal plant is wheat.

8. Use according to any one of Claims 1 to 7, wherein the cereal plant is hybrid wheat.

9. Use according to any one of Claims 1 to 8, characterized in that Isoflucypram is employed in combination with a further active fungicidal ingredient.

10. Use according to any one of Claims 1 to 9, characterized in that Isoflucypram is employed in combination with Prothioconazole or Tebuconazole.

11. Use according to any one of Claims 1 to 9, characterized in that Isoflucypram is employed in combination with Prothioconazole and Tebuconazole.